{"gene":"HLA-G","run_date":"2026-04-28T18:06:53","timeline":{"discoveries":[{"year":1987,"finding":"HLA-G (originally designated HLA-6.0) was identified as a non-HLA-A/B/C class I gene encoding a protein with a shortened cytoplasmic segment due to an in-frame stop codon that truncates the majority of the cytoplasmic tail, structurally resembling murine Qa-region class I genes.","method":"Genomic cloning, sequencing, and structural analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — original structural characterization by sequencing with functional domain analysis; foundational paper","pmids":["3480534"],"is_preprint":false},{"year":1990,"finding":"HLA-G protein is expressed as an array of five 37–39 kDa isoforms on first-trimester villous cytotrophoblasts and is greatly reduced in third-trimester cytotrophoblasts; it is not expressed in normal lymphoid cells, demonstrating cell-type-specific and developmental regulation.","method":"Two-dimensional gel electrophoresis, immunoprecipitation","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — direct protein detection by 2D-PAGE with biochemical characterization; foundational paper with high citations","pmids":["2326636"],"is_preprint":false},{"year":1990,"finding":"HLA-G encodes a truncated HLA class I heavy chain (~40 kDa) expressed on extravillous trophoblast and the choriocarcinoma cell line BeWo, confirmed by cDNA cloning and sequencing showing high homology to HLA-6.0 genomic clone.","method":"cDNA cloning, sequencing, RT-PCR, immunoprecipitation","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — cDNA cloning and protein immunoprecipitation; replicated findings from independent lab","pmids":["2295808"],"is_preprint":false},{"year":1992,"finding":"The HLA-G primary transcript is alternatively spliced to yield at least three distinct mature mRNAs encoding proteins resembling class I (full-length) and truncated forms (lacking alpha2 domain alone, or alpha2+alpha3 domains), with three corresponding protein products detected by immunoprecipitation.","method":"RT-PCR, sequencing of alternatively spliced transcripts, immunoprecipitation of [35S]methionine-labeled proteins","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — biochemical characterization of alternative splice isoforms with protein-level confirmation","pmids":["1570318"],"is_preprint":false},{"year":1995,"finding":"HLA-G protein expression is restricted to invasive cytotrophoblasts at the maternal-fetal interface and is up-regulated as cytotrophoblast stem cells differentiate along the invasive pathway in vitro, with term cytotrophoblasts (reduced invasive capacity) showing decreased HLA-G up-regulation.","method":"mAb generation using synthetic alpha1-domain peptide, immunoaffinity purification, immunohistochemistry on tissue sections, Northern blot","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — direct protein detection with custom mAbs, functional differentiation assay, replicated by multiple methods","pmids":["7706718"],"is_preprint":false},{"year":1996,"finding":"HLA-G molecules present peptides in a manner analogous to classical HLA molecules; the HLA-G peptide motif is defined as XI/LPXXXXXL with anchor residues at positions 2 (Ile/Leu), 3 (Pro), and 9 (Leu), and peptide-binding assays showed two of three anchors are sufficient for binding.","method":"Peptide elution from stably transfected LCL721.221 cells, individual and pool sequencing, peptide-binding assay","journal":"Current biology","confidence":"High","confidence_rationale":"Tier 1 — direct biochemical peptide elution and sequencing with binding assay validation","pmids":["8805247"],"is_preprint":false},{"year":1997,"finding":"Both HLA-G1 (full-length) and HLA-G2 (alpha1+alpha3 truncation) inhibit NK cell cytolysis; HLA-G2 is present at the cell surface associated with beta2-microglobulin; the alpha1 domain shared by G1 and G2 mediates protection from NK lysis; HLA-G was proposed as a 'public ligand' for NK inhibitory receptors.","method":"Stable transfection of K562 cells with HLA-G1 or HLA-G2 cDNA, NK cytolysis assay with polyclonal NK cells from 20 donors, mAb blocking","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — functional transfection experiments with blocking antibodies, replicated across 20 donors","pmids":["9144223"],"is_preprint":false},{"year":1997,"finding":"The impaired spontaneous endocytosis of HLA-G is caused by its short cytoplasmic tail; chimeric proteins carrying the HLA-G cytoplasmic tail (or GPI-anchored HLA-C) were not efficiently internalized, demonstrating that the truncated cytoplasmic tail of HLA-G is responsible for its prolonged cell-surface residence.","method":"Surface biotinylation, flow cytometric endocytosis assay, beta2-microglobulin exchange labeling with Texas red, chimeric protein constructs","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal methods including chimeric constructs and non-perturbative labeling approach","pmids":["9368631"],"is_preprint":false},{"year":1998,"finding":"ILT4 (expressed on monocytes, macrophages, and dendritic cells) binds both classical MHC class I molecules and the nonclassical HLA-G, transducing inhibitory signals via immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that recruit phosphatases and suppress early activation signaling in myelomonocytic cells.","method":"Receptor characterization by binding assays, ITIM-mediated signaling assay, transfection","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — direct receptor-ligand binding and downstream signaling characterization","pmids":["9531263"],"is_preprint":false},{"year":1999,"finding":"Soluble KIR2DL4 binds specifically to cells expressing HLA-G but not to cells expressing other HLA class I molecules; KIR2DL4 is expressed on all NK cells (unlike other clonally distributed KIRs); functional transfer of KIR2DL4 into NK-92 cells inhibits lysis of HLA-G+ targets but not HLA-E+ targets.","method":"Recombinant soluble KIR2DL4 binding assay, flow cytometry, functional NK cytotoxicity assay with KIR2DL4 transfectants","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — recombinant protein binding assay combined with functional transfer experiment; highly cited foundational paper","pmids":["10190900"],"is_preprint":false},{"year":1999,"finding":"NK recognition of HLA-G1 involves two non-overlapping receptor-ligand systems: (1) direct engagement of ILT2 (LIR1) by HLA-G1, and (2) CD94/NKG2A interaction with HLA-E co-expressed via binding to the nonamer peptide (VMAPRTLFL) from the HLA-G leader sequence.","method":"HLA-E-negative mutant transfectants (site-directed mutagenesis of HLA-G leader sequence), ILT2-Ig fusion protein binding assay, mAb blocking of CD94/NKG2A and ILT2","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis of leader sequence to ablate HLA-E induction, combined with receptor-specific blocking","pmids":["9933109"],"is_preprint":false},{"year":1999,"finding":"IL-10 selectively induces HLA-G gene transcription in trophoblasts and up-regulates HLA-G surface expression in peripheral blood monocytes, while simultaneously down-regulating classical MHC class I and MHC class II on monocytes, suggesting IL-10 as a tissue-specific activator of HLA-G expression at the fetal-maternal interface.","method":"Northern blot, RNase protection assay, RT-PCR, flow cytometry in trophoblast cultures and monocytes","journal":"International immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods; selective effect on HLA-G vs. classical HLA shown in same system","pmids":["10330285"],"is_preprint":false},{"year":2000,"finding":"Soluble HLA-G1 (sHLA-G1) triggers apoptosis in activated (but not resting) CD8+ peripheral blood cells through the CD95/CD95 ligand pathway; sHLA-G1 enhances CD95 ligand expression in activated CD8+ cells; this apoptosis depends on the interaction of sHLA-G1 with CD8 molecules, as CD8-specific mAbs block cell death.","method":"Affinity-purified sHLA-G1, Western blotting for CD95L, CD95-Fc and ZB4 blocking experiments, CD8 mAb blocking","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — biochemical purification with multiple blocking experiments defining the molecular pathway","pmids":["10843658"],"is_preprint":false},{"year":2001,"finding":"HLA-G2, -G3, and -G4 truncated isoforms reach the cell surface as endoglycosidase H-sensitive (immature) glycoproteins and protect transfected cells from both NK and CTL cytolysis, demonstrating that non-G1 membrane-bound isoforms are functional immunomodulatory molecules.","method":"Stable transfection, endoglycosidase H sensitivity assay, NK and CTL cytotoxicity assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — direct functional NK/CTL assays combined with glycosylation analysis of surface isoforms","pmids":["11290782"],"is_preprint":false},{"year":2002,"finding":"HLA-G forms disulfide-linked dimers on the cell surface via a disulfide bond exclusively through Cys-42; mutation of Cys-42 to serine completely abrogates dimerization; the ~78 kDa dimer is reduced to ~39 kDa by DTT.","method":"Surface biotinylation, immunoprecipitation with anti-beta2m mAb, DTT reduction, site-directed mutagenesis (Cys42Ser)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis identifying the specific cysteine residue responsible, combined with biochemical verification","pmids":["12454284"],"is_preprint":false},{"year":2003,"finding":"ILT2 and ILT4 bind HLA-G with 3- to 4-fold higher affinity than classical MHC class I molecules (KD values measured by surface plasmon resonance); ILT2 binds with 2- to 3-fold higher affinity than ILT4 to the same MHCI; ILT2 and ILT4 compete with CD8 for MHC class I binding.","method":"Surface plasmon resonance (SPR) with soluble ILT2 and ILT4 proteins against multiple MHC class I molecules; CD8 competition assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — quantitative biophysical binding measurements with defined recombinant proteins","pmids":["12853576"],"is_preprint":false},{"year":2003,"finding":"Melanoma cells release exosomes bearing HLA-G1; these HLA-G1-positive exosomes are also secreted by HLA-G-negative melanoma cells transfected with HLA-G1 cDNA, providing a mechanism for tumor immune modulation via secreted vesicles.","method":"Sucrose gradient ultracentrifugation, Western blotting, flow cytometry of purified exosomes","journal":"Human immunology","confidence":"Medium","confidence_rationale":"Tier 2 — direct biochemical purification and characterization of exosomes; single lab","pmids":["14602237"],"is_preprint":false},{"year":2003,"finding":"HLA-G1 inhibits NK- and CTL-mediated lysis via ILT2 and ILT4; HLA-G5 (soluble) binds CD8 and induces Fas/FasL-mediated apoptosis in activated CD8+ lymphocytes; KIR2DL4 engagement triggers different responses depending on effector cell activation state.","method":"Functional cytotoxicity assays, receptor-ligand characterization","journal":"Seminars in cancer biology","confidence":"Medium","confidence_rationale":"Tier 3 — review synthesizing experimental findings; individual mechanistic findings supported by primary papers already cited","pmids":["14708711"],"is_preprint":false},{"year":2004,"finding":"Soluble HLA-G1 can be generated by metalloproteinase-dependent shedding of membrane-bound HLA-G1 at the post-translational level; shed sHLA-G1 associates with beta2-microglobulin, contains bound peptides stable at physiological conditions, and protects HLA class I-negative K562 cells from NK lysis.","method":"Metalloproteinase inhibitor experiments, Western blotting, NK cytotoxicity assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological inhibitor defining mechanism of shedding with functional NK lysis readout; single lab","pmids":["14697234"],"is_preprint":false},{"year":2005,"finding":"HLA-G binding to ILT4 on dendritic cells induces tolerogenic DC with arrested maturation/activation; HLA-G-modified DCs induce anergic and immunosuppressive CD4+ and CD8+ T cells; ILT4 ligation on DCs disrupts MHC class II antigen presentation pathway and significantly prolongs allograft survival in ILT4-transgenic mice.","method":"Human monocyte-derived DC assays, ILT4-transgenic mouse model, gene expression profiling, allograft survival experiments","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — in vitro human DC system combined with in vivo transgenic mouse allograft model with functional readouts","pmids":["15770701"],"is_preprint":false},{"year":2005,"finding":"Residues Met76 and Gln79 in the alpha1 domain of HLA-G are critical for KIR2DL4 recognition; mutation of these residues to Ala reduces binding of KIR2DL4-IgG Fc fusion protein to HLA-G and alters KIR2DL4-transfected NK-92 cell cytolysis against HLA-G-expressing targets.","method":"Retroviral transduction, KIR2DL4-IgG Fc fusion protein binding assay, NK cytotoxicity assay with KIR2DL4-transfected NK-92 cells","journal":"Cell research","confidence":"Medium","confidence_rationale":"Tier 2 — site-directed mutagenesis with functional binding and cytolysis assays; single lab","pmids":["15780179"],"is_preprint":false},{"year":2007,"finding":"MSCs secrete the soluble isoform HLA-G5 in an IL-10-dependent manner; cell contact between MSCs and allostimulated T cells is required for full HLA-G5 secretion; blocking HLA-G5 with neutralizing antibody reveals it suppresses allogeneic T-cell proliferation, expands CD4+CD25highFOXP3+ regulatory T cells, inhibits NK-mediated cytolysis, and inhibits IFN-gamma secretion by NK cells.","method":"Neutralizing anti-HLA-G antibody blocking, IL-10 pathway inhibition, flow cytometry, cytotoxicity assays","journal":"Stem cells","confidence":"High","confidence_rationale":"Tier 2 — multiple functional readouts with specific antibody blocking; highly cited paper replicating HLA-G5 function","pmids":["17932417"],"is_preprint":false},{"year":2010,"finding":"Tr1 cell differentiation by DC-10 (IL-10-producing tolerogenic DCs that express ILT4 and HLA-G) is IL-10-dependent and requires the ILT4/HLA-G signaling pathway; DC-10 induce antigen-specific IL-10-producing Tr1 cells through this pathway.","method":"DC-10 isolation from peripheral blood and in vitro differentiation, Tr1 induction assays, pathway blocking experiments","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — specific pathway blocking with functional T-cell differentiation readout; highly cited paper","pmids":["20448110"],"is_preprint":false},{"year":2012,"finding":"KIR2DL4 resides in endosomes (not on the cell surface like other KIRs); soluble HLA-G accumulates in KIR2DL4+ endosomes; KIR2DL4 signals from this intracellular site for a proinflammatory and proangiogenic response using a novel endosomal signaling pathway involving serine/threonine kinases DNA-PKcs and Akt.","method":"Subcellular localization studies, endosomal fractionation, kinase pathway analysis","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 — subcellular localization with defined signaling pathway identification; review citing primary experimental work","pmids":["22934097"],"is_preprint":false},{"year":2013,"finding":"Two synthetic HLA-G-derived molecules—(α3-L)x2 and (α1-α3)x2 polypeptides—bind the HLA-G receptor LILRB2; (α1-α3)x2 prolongs allograft survival in mice (one treatment significantly prolongs, four weekly treatments induce complete tolerance) and inhibits tumor cell line proliferation as does full-length HLA-G.","method":"Receptor binding assay with LILRB2, in vivo murine skin allograft model, in vitro tumor proliferation assay","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 — recombinant protein binding combined with in vivo functional validation in allograft model","pmids":["23752205"],"is_preprint":false},{"year":2015,"finding":"HLA-G interaction with HLA-G+ extravillous trophoblasts (EVT) and decidual CD4+ T cells results in increased numbers of CD4+CD25hiIFOXP3+CD45RA+ resting regulatory T cells (Tregs) and increased FOXP3 expression, providing a mechanism by which EVT maintain fetal-maternal tolerance.","method":"Purification of primary HLA-G+ EVT by FACS, coculture assays with decidual NK cells, macrophages, CD4+ and CD8+ T cells; microarray gene expression analysis; flow cytometry","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — highly purified primary cell cocultures with functional Treg induction readout and gene expression profiling","pmids":["26015573"],"is_preprint":false},{"year":2016,"finding":"A trophoblast-specific cis-regulatory enhancer (Enhancer L) located 12 kb upstream of HLA-G controls tissue-specific HLA-G expression; CRISPR/Cas9-mediated deletion of Enhancer L ablates HLA-G expression in JEG3 cells and primary human trophoblasts; Enhancer L loops into the HLA-G promoter via chromatin conformation capture; CEBP and GATA family transcription factors bind Enhancer L and regulate HLA-G expression.","method":"Massively parallel reporter assay (MPRA), CRISPR/Cas9 deletion, RNA-seq, DNase-seq, chromatin conformation capture (3C), saturation mutagenesis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal genomic and editing methods with functional validation in primary cells","pmids":["27078102"],"is_preprint":false},{"year":2003,"finding":"The 14 bp insertion polymorphism in the 3' UTR of HLA-G generates an additional splice that removes 92 bases from exon 8; HLA-G mRNAs with this 92-base deletion are more stable than complete mRNA forms, demonstrating that this region controls post-transcriptional regulation of HLA-G expression.","method":"Actinomycin D mRNA stability assays in JEG-3 and transfected M8 melanoma cells, RT-PCR","journal":"Human immunology","confidence":"Medium","confidence_rationale":"Tier 2 — direct mRNA stability measurement in relevant cell lines; single lab","pmids":["14602228"],"is_preprint":false},{"year":2012,"finding":"A LINE1 sequence upstream of HLA-G functions as a negative regulator of HLA-G gene expression; HLA-G silencing involves a DNA secondary structure generated within the LINE1 element, as shown by manipulation of a single genomic copy on a human artificial chromosome.","method":"Human artificial chromosome system with single-copy genomic manipulation, reporter assays, DNA secondary structure analysis","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 — single-copy genomic manipulation with functional silencing readout; single lab","pmids":["23002136"],"is_preprint":false},{"year":2015,"finding":"DNMT-1-mediated promoter hypermethylation suppresses HLA-G expression; CpG sites in the HLA-G promoter are significantly more methylated in preeclampsia; treatment with DNMT inhibitor 5-aza-2'-deoxycytidine or DNMT-1 siRNA knockdown significantly increases HLA-G expression in a trophoblastic cell line.","method":"Bisulfite pyrosequencing, siRNA knockdown, 5-aza-2'-deoxycytidine treatment, qPCR, immunohistochemistry","journal":"Molecular human reproduction","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological and genetic manipulation of DNMT-1 with functional HLA-G expression readout","pmids":["26116450"],"is_preprint":false},{"year":2007,"finding":"Soluble HLA-G1 (HLA-G5) inhibits endothelial cell proliferation, migration, and tubule formation through binding to the CD160 receptor via an apoptotic pathway; soluble HLA-G1 also blocks in vivo rabbit corneal neoangiogenesis, demonstrating anti-angiogenic properties.","method":"In vitro endothelial cell proliferation, migration and tubule formation assays, CD160 receptor binding, in vivo rabbit corneal neoangiogenesis model","journal":"Journal of reproductive immunology","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro receptor-mediated mechanism combined with in vivo functional validation","pmids":["17467060"],"is_preprint":false}],"current_model":"HLA-G is a nonclassical MHC class I molecule with a truncated cytoplasmic tail (causing impaired endocytosis and prolonged surface residence) that is alternatively spliced into at least seven isoforms (four membrane-bound, three soluble); it presents peptides via a defined motif (XI/LPXXXXXL), forms disulfide-linked dimers via Cys-42, and exerts immune tolerance by directly binding inhibitory receptors ILT2, ILT4 (with 3–4-fold higher affinity than classical MHC-I), and KIR2DL4 (the latter signaling from endosomes via DNA-PKcs/Akt for proangiogenic responses), inducing tolerogenic DCs, regulatory T cells, and NK senescence, while soluble HLA-G1 triggers CD95/FasL-mediated apoptosis in activated CD8+ T cells via CD8 interaction and inhibits endothelial angiogenesis via CD160; tissue-specific expression in trophoblasts is controlled by a distal enhancer (Enhancer L, 12 kb upstream) looping to the HLA-G promoter via CEBP/GATA transcription factors, with post-transcriptional regulation by 3'UTR 14-bp insertion polymorphism affecting mRNA stability, IL-10-dependent transcriptional induction, LINE1-mediated silencing, and DNMT-1-mediated promoter methylation."},"narrative":{"teleology":[{"year":1987,"claim":"Identification of HLA-G as a non-classical class I gene with a truncated cytoplasmic tail established it as structurally distinct from HLA-A/B/C and predicted unusual trafficking or signaling properties.","evidence":"Genomic cloning and sequencing revealing an in-frame stop codon shortening the cytoplasmic domain","pmids":["3480534"],"confidence":"High","gaps":["No protein expression data yet","No functional consequence of tail truncation demonstrated","Tissue distribution unknown"]},{"year":1990,"claim":"Demonstrating that HLA-G protein is selectively expressed on first-trimester cytotrophoblasts but absent from lymphoid cells answered whether HLA-G had tissue-restricted expression and immediately implicated it in maternal–fetal immune regulation.","evidence":"2D gel electrophoresis and immunoprecipitation on trophoblast and lymphoid cells; independent cDNA cloning from extravillous trophoblast and BeWo choriocarcinoma","pmids":["2326636","2295808"],"confidence":"High","gaps":["Mechanism of tissue restriction unknown","Functional role at the maternal–fetal interface not yet demonstrated"]},{"year":1992,"claim":"Discovery of at least three alternatively spliced isoforms (including truncated forms lacking alpha2 or alpha2+alpha3 domains) expanded the functional repertoire of HLA-G beyond a single membrane-bound protein.","evidence":"RT-PCR with immunoprecipitation of [35S]-labeled proteins confirming three distinct protein products","pmids":["1570318"],"confidence":"High","gaps":["Whether truncated isoforms reach the cell surface and are functional was unresolved","Soluble isoforms not yet characterized"]},{"year":1996,"claim":"Defining the HLA-G peptide-binding motif (XI/LPXXXXXL) established that HLA-G presents peptides analogously to classical MHC-I, raising the question of whether its immunomodulatory function requires specific peptide loading.","evidence":"Peptide elution from HLA-G-expressing LCL721.221 transfectants, pool sequencing, and peptide-binding assays","pmids":["8805247"],"confidence":"High","gaps":["Identity of physiologically presented peptides at the maternal–fetal interface unknown","Whether peptide identity affects receptor engagement undetermined"]},{"year":1997,"claim":"Functional evidence that HLA-G1 and HLA-G2 isoforms both inhibit NK cell lysis, combined with demonstration that the truncated cytoplasmic tail impairs endocytosis, established HLA-G as a stable surface-resident NK inhibitory ligand functioning through the alpha1 domain.","evidence":"NK cytolysis assays with HLA-G1/G2-transfected K562 cells across 20 donors; surface biotinylation and chimeric construct endocytosis assays","pmids":["9144223","9368631"],"confidence":"High","gaps":["Specific inhibitory receptors mediating NK inhibition not yet identified","Whether all truncated isoforms are functional was unknown"]},{"year":1999,"claim":"Identification of ILT2, ILT4, and KIR2DL4 as three distinct HLA-G receptors, together with the indirect pathway via HLA-E/CD94-NKG2A, resolved how HLA-G inhibits diverse immune effector cell types through both direct and indirect recognition systems.","evidence":"ILT4 ITIM signaling assays; recombinant KIR2DL4 binding to HLA-G+ cells with functional transfer into NK-92; HLA-E leader-sequence mutagenesis combined with ILT2-Ig and CD94/NKG2A blocking","pmids":["9531263","10190900","9933109"],"confidence":"High","gaps":["Quantitative binding affinities for each receptor not yet measured","Signaling pathways downstream of each receptor not characterized","KIR2DL4 binding site on HLA-G unmapped"]},{"year":2000,"claim":"Showing that soluble HLA-G1 induces apoptosis in activated CD8+ T cells via CD8-dependent upregulation of CD95L/Fas revealed a cytotoxic effector deletion mechanism distinct from receptor-mediated inhibition.","evidence":"Affinity-purified sHLA-G1 with CD95-Fc, ZB4, and CD8 mAb blocking experiments","pmids":["10843658"],"confidence":"High","gaps":["Whether this pathway operates in vivo at the maternal–fetal interface not shown","Threshold of sHLA-G1 concentration required for apoptosis undefined"]},{"year":2002,"claim":"Identification of Cys-42 as the sole residue mediating HLA-G disulfide-linked dimerization defined a structural feature unique among MHC-I molecules that enhances receptor avidity.","evidence":"Site-directed mutagenesis (Cys42Ser) with surface biotinylation and DTT reduction","pmids":["12454284"],"confidence":"High","gaps":["Whether dimeric HLA-G has differential receptor-binding properties versus monomer not quantified","Crystal structure of the dimer not yet available"]},{"year":2003,"claim":"Quantitative SPR measurements showing 3–4-fold higher affinity of ILT2 and ILT4 for HLA-G versus classical MHC-I, combined with demonstration that ILT2/ILT4 compete with CD8, established the biophysical basis for preferential immune inhibition by HLA-G.","evidence":"Surface plasmon resonance with recombinant ILT2, ILT4, and multiple MHC-I; CD8 competition assay","pmids":["12853576"],"confidence":"High","gaps":["Structural basis for enhanced affinity not elucidated","Impact of dimerization on measured affinities not assessed"]},{"year":2003,"claim":"The 14-bp insertion polymorphism in the HLA-G 3′ UTR was shown to generate a more stable spliced mRNA, providing a genetic mechanism for inter-individual variation in HLA-G expression levels.","evidence":"Actinomycin D mRNA stability assays in JEG-3 and transfected M8 melanoma cells","pmids":["14602228"],"confidence":"Medium","gaps":["Whether mRNA stability differences translate to proportional protein-level differences in vivo not demonstrated","Trans-acting factors mediating differential stability not identified"]},{"year":2005,"claim":"Demonstration that HLA-G/ILT4 engagement arrests DC maturation, disrupts MHC-II presentation, and induces tolerogenic DCs that generate anergic T cells—prolonging allograft survival in ILT4-transgenic mice—linked HLA-G to adaptive immune tolerance induction beyond NK inhibition.","evidence":"Human monocyte-derived DC assays combined with ILT4-transgenic mouse allograft model","pmids":["15770701"],"confidence":"High","gaps":["Intracellular signaling cascade downstream of ILT4 in DCs incompletely defined","Whether this pathway functions identically in human tissues in vivo not confirmed"]},{"year":2007,"claim":"Soluble HLA-G5 secreted by MSCs in an IL-10-dependent manner was shown to suppress T-cell proliferation and expand FOXP3+ Tregs, extending HLA-G function beyond the trophoblast to MSC-mediated immunomodulation, while soluble HLA-G1 inhibited angiogenesis through CD160 in vitro and in vivo.","evidence":"Anti-HLA-G neutralizing antibody blocking in MSC–T cell cocultures; endothelial cell assays and rabbit corneal neoangiogenesis model with CD160 receptor binding","pmids":["17932417","17467060"],"confidence":"High","gaps":["Whether HLA-G5 is the principal effector of MSC immunosuppression or one of several redundant mechanisms unknown","CD160 signaling pathway downstream of HLA-G binding not fully characterized"]},{"year":2012,"claim":"The finding that KIR2DL4 resides in endosomes and signals via DNA-PKcs/Akt after capturing soluble HLA-G revealed an unconventional endosomal immune signaling pathway, while LINE1-mediated chromatin silencing upstream of HLA-G added an epigenetic layer of expression control.","evidence":"Endosomal fractionation and kinase pathway analysis for KIR2DL4; human artificial chromosome system with single-copy LINE1 manipulation","pmids":["22934097","23002136"],"confidence":"Medium","gaps":["KIR2DL4 endosomal signaling characterized largely from one group; independent replication needed","How LINE1 secondary structure recruits silencing factors not defined"]},{"year":2015,"claim":"Primary HLA-G+ extravillous trophoblasts were directly shown to expand resting FOXP3+ Tregs in decidual tissue, providing in situ evidence for HLA-G-driven tolerance at the maternal–fetal interface, while DNMT-1-mediated promoter methylation was identified as a mechanism that suppresses HLA-G in preeclampsia.","evidence":"FACS-purified primary EVT coculture with decidual immune cells and microarray profiling; bisulfite pyrosequencing with DNMT-1 siRNA/5-aza-CdR in trophoblast cells","pmids":["26015573","26116450"],"confidence":"High","gaps":["Whether DNMT-1-mediated silencing is causally linked to preeclampsia pathogenesis or a secondary effect not established","Relative contributions of individual immune cell types to Treg expansion not dissected"]},{"year":2016,"claim":"CRISPR/Cas9 deletion of Enhancer L (12 kb upstream) ablated HLA-G expression, and chromatin conformation capture showed Enhancer L loops to the promoter via CEBP/GATA factors, resolving the long-standing question of how trophoblast-specific transcription is achieved.","evidence":"MPRA, CRISPR/Cas9 deletion in JEG3 and primary trophoblasts, RNA-seq, DNase-seq, 3C, saturation mutagenesis","pmids":["27078102"],"confidence":"High","gaps":["Whether Enhancer L operates in non-trophoblast contexts (e.g., tumors, MSCs) not tested","Complete set of transcription factors required at Enhancer L not defined"]},{"year":null,"claim":"Key open questions include: (1) structural determination of how HLA-G dimers engage ILT2/ILT4 versus KIR2DL4; (2) the in vivo hierarchy among the multiple receptor pathways for maternal–fetal tolerance; (3) whether tumor exploitation of HLA-G recapitulates the same receptor/signaling axis as trophoblast-driven tolerance.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal structure of HLA-G dimer–receptor complex available","In vivo redundancy among ILT2, ILT4, KIR2DL4, and HLA-E pathways not delineated","Relative importance of membrane-bound versus soluble isoforms in tumor immune evasion not resolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[6,8,9,10,12,15,17]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[6,9,15]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,4,7,13,14]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[12,18,21,30]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[23]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[16]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6,8,9,10,12,15,19,21,22,25]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[8,19,23]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[12]}],"complexes":["MHC class I/beta2-microglobulin/peptide complex","HLA-G Cys42-linked homodimer"],"partners":["ILT2","ILT4","KIR2DL4","B2M","CD8A","CD160","CD94","NKG2A"],"other_free_text":[]},"mechanistic_narrative":"HLA-G is a nonclassical MHC class I molecule with restricted expression on extravillous trophoblasts that functions as a master mediator of immune tolerance at the maternal–fetal interface and in other immunoprivileged contexts. Its truncated cytoplasmic tail impairs endocytosis, prolonging surface residence [PMID:9368631], and its primary transcript undergoes alternative splicing to produce at least four membrane-bound and three soluble isoforms, all capable of inhibiting NK- and CTL-mediated cytolysis [PMID:1570318, PMID:11290782]. HLA-G presents peptides via a defined XI/LPXXXXXL motif [PMID:8805247] and forms disulfide-linked dimers through Cys-42 [PMID:12454284]; it engages the inhibitory receptors ILT2 and ILT4 with 3–4-fold higher affinity than classical MHC-I to induce tolerogenic dendritic cells and regulatory T cells, KIR2DL4 from endosomes to elicit proangiogenic signaling, and CD8 on activated T cells to trigger Fas/FasL-mediated apoptosis [PMID:12853576, PMID:15770701, PMID:10190900, PMID:10843658]. Trophoblast-specific expression is governed by a distal enhancer (Enhancer L, ~12 kb upstream) occupied by CEBP/GATA factors and looping to the promoter, with additional regulation by IL-10-dependent transcription, DNMT-1-mediated promoter methylation, a LINE1-based silencing element, and a 3′ UTR 14-bp insertion polymorphism that modulates mRNA stability [PMID:27078102, PMID:10330285, PMID:26116450, PMID:23002136, PMID:14602228]."},"prefetch_data":{"uniprot":{"accession":"P17693","full_name":"HLA class I histocompatibility antigen, alpha chain G","aliases":["HLA G antigen","MHC class I antigen G"],"length_aa":338,"mass_kda":38.2,"function":"Non-classical major histocompatibility class Ib molecule involved in immune regulatory processes at the maternal-fetal interface (PubMed:19304799, PubMed:23184984, PubMed:29262349). In complex with B2M/beta-2 microglobulin binds a limited repertoire of nonamer self-peptides derived from intracellular proteins including histones and ribosomal proteins (PubMed:7584149, PubMed:8805247). Peptide-bound HLA-G-B2M complex acts as a ligand for inhibitory/activating KIR2DL4, LILRB1 and LILRB2 receptors on uterine immune cells to promote fetal development while maintaining maternal-fetal tolerance (PubMed:16366734, PubMed:19304799, PubMed:20448110, PubMed:23184984, PubMed:27859042, PubMed:29262349). Upon interaction with KIR2DL4 and LILRB1 receptors on decidual NK cells, it triggers NK cell senescence-associated secretory phenotype as a molecular switch to promote vascular remodeling and fetal growth in early pregnancy (PubMed:16366734, PubMed:19304799, PubMed:23184984, PubMed:29262349). Through interaction with KIR2DL4 receptor on decidual macrophages induces pro-inflammatory cytokine production mainly associated with tissue remodeling (PubMed:19304799). Through interaction with LILRB2 receptor triggers differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, both of which actively maintain maternal-fetal tolerance (PubMed:20448110, PubMed:27859042). May play a role in balancing tolerance and antiviral-immunity at maternal-fetal interface by keeping in check the effector functions of NK, CD8+ T cells and B cells (PubMed:10190900, PubMed:11290782, PubMed:24453251). Reprograms B cells toward an immune suppressive phenotype via LILRB1 (PubMed:24453251). May induce immune activation/suppression via intercellular membrane transfer (trogocytosis), likely enabling interaction with KIR2DL4, which resides mostly in endosomes (PubMed:20179272, PubMed:26460007). Through interaction with the inhibitory receptor CD160 on endothelial cells may control angiogenesis in immune privileged sites (PubMed:16809620) Likely does not bind B2M and presents peptides. Negatively regulates NK cell- and CD8+ T cell-mediated cytotoxicity (PubMed:11290782) Likely does not bind B2M and presents peptides. Negatively regulates NK cell- and CD8+ T cell-mediated cytotoxicity (PubMed:11290782) Likely does not bind B2M and presents peptides. Negatively regulates NK cell- and CD8+ T cell-mediated cytotoxicity (PubMed:11290782) Non-classical major histocompatibility class Ib molecule involved in immune regulatory processes at the maternal-fetal interface (PubMed:19304799, PubMed:23184984, PubMed:29262349). In complex with B2M/beta-2 microglobulin binds a limited repertoire of nonamer self-peptides derived from intracellular proteins including histones and ribosomal proteins (PubMed:7584149, PubMed:8805247). Peptide-bound HLA-G-B2M complex acts as a ligand for inhibitory/activating KIR2DL4, LILRB1 and LILRB2 receptors on uterine immune cells to promote fetal development while maintaining maternal-fetal tolerance (PubMed:16366734, PubMed:19304799, PubMed:20448110, PubMed:23184984, PubMed:29262349). Upon interaction with KIR2DL4 and LILRB1 receptors on decidual NK cells, it triggers NK cell senescence-associated secretory phenotype as a molecular switch to promote vascular remodeling and fetal growth in early pregnancy (PubMed:16366734, PubMed:19304799, PubMed:23184984, PubMed:29262349). Through interaction with KIR2DL4 receptor on decidual macrophages induces pro-inflammatory cytokine production mainly associated with tissue remodeling (PubMed:19304799). Through interaction with LILRB2 receptor triggers differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, both of which actively maintain maternal-fetal tolerance (PubMed:20448110). Reprograms B cells toward an immune suppressive phenotype via LILRB1 (PubMed:24453251) Likely does not bind B2M and presents peptides Likely does not bind B2M and presents peptides","subcellular_location":"Cell projection, filopodium membrane","url":"https://www.uniprot.org/uniprotkb/P17693/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HLA-G","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/HLA-G","total_profiled":1310},"omim":[{"mim_id":"614389","title":"PREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 1; RPRGL1","url":"https://www.omim.org/entry/614389"},{"mim_id":"602619","title":"C-TERMINAL-BINDING PROTEIN 2; CTBP2","url":"https://www.omim.org/entry/602619"},{"mim_id":"602618","title":"C-TERMINAL-BINDING PROTEIN 1; CTBP1","url":"https://www.omim.org/entry/602618"},{"mim_id":"602209","title":"RAS-RESPONSIVE ELEMENT BINDING PROTEIN 1; RREB1","url":"https://www.omim.org/entry/602209"},{"mim_id":"600807","title":"ASTHMA, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/600807"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"pituitary gland","ntpm":13.7},{"tissue":"placenta","ntpm":10.5}],"url":"https://www.proteinatlas.org/search/HLA-G"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P17693","domains":[{"cath_id":"3.30.500.10","chopping":"25-203","consensus_level":"high","plddt":97.2472,"start":25,"end":203},{"cath_id":"2.60.40.10","chopping":"209-296","consensus_level":"high","plddt":95.3301,"start":209,"end":296}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P17693","model_url":"https://alphafold.ebi.ac.uk/files/AF-P17693-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P17693-F1-predicted_aligned_error_v6.png","plddt_mean":90.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HLA-G","jax_strain_url":"https://www.jax.org/strain/search?query=HLA-G"},"sequence":{"accession":"P17693","fasta_url":"https://rest.uniprot.org/uniprotkb/P17693.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P17693/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P17693"}},"corpus_meta":[{"pmid":"7706718","id":"PMC_7706718","title":"Human placental HLA-G expression is restricted to differentiated cytotrophoblasts.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7706718","citation_count":383,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26073983","id":"PMC_26073983","title":"HLA-G: An Immune Checkpoint Molecule.","date":"2015","source":"Advances in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26073983","citation_count":327,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17847008","id":"PMC_17847008","title":"Allele-specific targeting of microRNAs to HLA-G and risk of asthma.","date":"2007","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17847008","citation_count":316,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21107637","id":"PMC_21107637","title":"Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association.","date":"2010","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/21107637","citation_count":260,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15770701","id":"PMC_15770701","title":"Tolerization of dendritic cells by HLA-G.","date":"2005","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15770701","citation_count":258,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16280356","id":"PMC_16280356","title":"HLA-G in human reproduction: aspects of genetics, function and pregnancy complications.","date":"2005","source":"Human reproduction update","url":"https://pubmed.ncbi.nlm.nih.gov/16280356","citation_count":226,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14602233","id":"PMC_14602233","title":"Expression of HLA-G in human cornea, an immune-privileged tissue.","date":"2003","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14602233","citation_count":211,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12454284","id":"PMC_12454284","title":"Disulfide bond-mediated dimerization of HLA-G on the cell surface.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12454284","citation_count":173,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8805247","id":"PMC_8805247","title":"Nonclassical HLA-G molecules are classical peptide presenters.","date":"1996","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/8805247","citation_count":170,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10082427","id":"PMC_10082427","title":"Detection of soluble HLA-G molecules in plasma and amniotic fluid.","date":"1999","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/10082427","citation_count":167,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26015573","id":"PMC_26015573","title":"Human HLA-G+ extravillous trophoblasts: Immune-activating cells that interact with decidual leukocytes.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26015573","citation_count":166,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18538632","id":"PMC_18538632","title":"A critical look at HLA-G.","date":"2008","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18538632","citation_count":160,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22537084","id":"PMC_22537084","title":"The immunosuppressive molecule HLA-G and its clinical implications.","date":"2012","source":"Critical reviews in clinical laboratory sciences","url":"https://pubmed.ncbi.nlm.nih.gov/22537084","citation_count":151,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22934097","id":"PMC_22934097","title":"KIR2DL4 (CD158d): An activation receptor for HLA-G.","date":"2012","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22934097","citation_count":150,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17825579","id":"PMC_17825579","title":"Soluble HLA-G: Are they clinically relevant?","date":"2007","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/17825579","citation_count":146,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10319265","id":"PMC_10319265","title":"The functionality of HLA-G is emerging.","date":"1999","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/10319265","citation_count":143,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14697234","id":"PMC_14697234","title":"Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/14697234","citation_count":139,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33193435","id":"PMC_33193435","title":"Roles of HLA-G in the Maternal-Fetal Immune Microenvironment.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33193435","citation_count":126,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11719594","id":"PMC_11719594","title":"HLA-G genotypes and pregnancy outcome in couples with unexplained recurrent miscarriage.","date":"2001","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/11719594","citation_count":117,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30319626","id":"PMC_30319626","title":"Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30319626","citation_count":113,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21063893","id":"PMC_21063893","title":"Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?","date":"2010","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/21063893","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25339953","id":"PMC_25339953","title":"Insights into HLA-G Genetics Provided by Worldwide Haplotype Diversity.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25339953","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14602237","id":"PMC_14602237","title":"Exosomes bearing HLA-G are released by melanoma cells.","date":"2003","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14602237","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23897901","id":"PMC_23897901","title":"Molecular pathways: human leukocyte antigen G (HLA-G).","date":"2013","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/23897901","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25477881","id":"PMC_25477881","title":"HLA-G Molecules in Autoimmune Diseases and Infections.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25477881","citation_count":98,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25143957","id":"PMC_25143957","title":"HLA-G as a tolerogenic molecule in transplantation and pregnancy.","date":"2014","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/25143957","citation_count":96,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24800261","id":"PMC_24800261","title":"The dual role of HLA-G in cancer.","date":"2014","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/24800261","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16306594","id":"PMC_16306594","title":"Modulation of HLA-G expression in human neural cells after neurotropic viral infections.","date":"2005","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/16306594","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19508383","id":"PMC_19508383","title":"Non-classical transcriptional regulation of HLA-G: an update.","date":"2009","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19508383","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17881247","id":"PMC_17881247","title":"Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses.","date":"2007","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/17881247","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24998350","id":"PMC_24998350","title":"HLA-G-mediated NK cell senescence promotes vascular remodeling: implications for reproduction.","date":"2014","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24998350","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18817832","id":"PMC_18817832","title":"HLA-G-dependent suppressor cells: Diverse by nature, function, and significance.","date":"2008","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18817832","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24818168","id":"PMC_24818168","title":"Some basic aspects of HLA-G biology.","date":"2014","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/24818168","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21960588","id":"PMC_21960588","title":"The tolerogenic interplay(s) among HLA-G, myeloid APCs, and regulatory cells.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21960588","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8178845","id":"PMC_8178845","title":"Expression of the nonclassic histocompatibility antigen HLA-G by preeclamptic placenta.","date":"1994","source":"American journal of obstetrics and gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/8178845","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15780179","id":"PMC_15780179","title":"Residues Met76 and Gln79 in HLA-G alpha1 domain involve in KIR2DL4 recognition.","date":"2005","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15780179","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27078102","id":"PMC_27078102","title":"A distant trophoblast-specific enhancer controls HLA-G expression at the maternal-fetal interface.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27078102","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24839609","id":"PMC_24839609","title":"Immunomodulatory properties of HLA-G in infectious diseases.","date":"2014","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/24839609","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32630545","id":"PMC_32630545","title":"HLA-G: A New Immune Checkpoint in Cancer?","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32630545","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10092545","id":"PMC_10092545","title":"The immunotolerance role of HLA-G.","date":"1999","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/10092545","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16916651","id":"PMC_16916651","title":"Soluble HLA-G in rheumatoid arthritis.","date":"2006","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16916651","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34276691","id":"PMC_34276691","title":"HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34276691","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9430736","id":"PMC_9430736","title":"HLA-G polymorphisms: neutral evolution or novel function?","date":"1997","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9430736","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10225437","id":"PMC_10225437","title":"Expression of HLA G in human tumors is not a frequent event.","date":"1999","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10225437","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14708711","id":"PMC_14708711","title":"HLA-G modulates immune responses by diverse receptor interactions.","date":"2003","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/14708711","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24860568","id":"PMC_24860568","title":"Controlling the Immunological Crosstalk during Conception and Pregnancy: HLA-G in Reproduction.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24860568","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12896824","id":"PMC_12896824","title":"HLA-G, pre-eclampsia, immunity and vascular events.","date":"2003","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12896824","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14602240","id":"PMC_14602240","title":"Soluble HLA-G molecules are increased in lymphoproliferative disorders.","date":"2003","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14602240","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25132109","id":"PMC_25132109","title":"New insights into HLA-G mediated tolerance.","date":"2014","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/25132109","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17118165","id":"PMC_17118165","title":"The role of HLA-G in human pregnancy.","date":"2006","source":"Reproductive biology and endocrinology : RB&E","url":"https://pubmed.ncbi.nlm.nih.gov/17118165","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11821155","id":"PMC_11821155","title":"Lung macrophages and dendritic cells express HLA-G molecules in pulmonary diseases.","date":"2002","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11821155","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17445190","id":"PMC_17445190","title":"Quantification and identification of soluble HLA-G isoforms.","date":"2007","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/17445190","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21080027","id":"PMC_21080027","title":"Emerging topics and new perspectives on HLA-G.","date":"2010","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/21080027","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32922387","id":"PMC_32922387","title":"HLA-G Neo-Expression on Tumors.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32922387","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19656137","id":"PMC_19656137","title":"Immunohistochemical study of HLA-G expression in lung transplant recipients.","date":"2009","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/19656137","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35154112","id":"PMC_35154112","title":"HLA-G: Too Much or Too Little? Role in Cancer and Autoimmune Disease.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35154112","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9619769","id":"PMC_9619769","title":"HLA-G polymorphisms and allele frequencies in Caucasians.","date":"1998","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9619769","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21116680","id":"PMC_21116680","title":"The role of HLA-G in immunity and hematopoiesis.","date":"2010","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/21116680","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32581122","id":"PMC_32581122","title":"Three types of HLA-G+ extravillous trophoblasts that have distinct immune regulatory properties.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32581122","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11137216","id":"PMC_11137216","title":"HLA-G truncated isoforms can substitute for HLA-G1 in fetal survival.","date":"2000","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11137216","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25772038","id":"PMC_25772038","title":"Biology of the immunomodulatory molecule HLA-G in human liver diseases.","date":"2015","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/25772038","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16214086","id":"PMC_16214086","title":"Immuno-tolerogenic functions of HLA-G: relevance in transplantation and oncology.","date":"2005","source":"Autoimmunity reviews","url":"https://pubmed.ncbi.nlm.nih.gov/16214086","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9368631","id":"PMC_9368631","title":"Impaired spontaneous endocytosis of HLA-G.","date":"1997","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9368631","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18691135","id":"PMC_18691135","title":"HLA-G and inflammatory diseases.","date":"2008","source":"Inflammation & allergy drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/18691135","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32733439","id":"PMC_32733439","title":"HLA-G Genotype/Expression/Disease Association Studies: Success, Hurdles, and Perspectives.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32733439","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21459722","id":"PMC_21459722","title":"Expression of HLA-G in patients with hepatocellular carcinoma.","date":"2011","source":"Hepatobiliary & pancreatic diseases international : HBPD INT","url":"https://pubmed.ncbi.nlm.nih.gov/21459722","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17467060","id":"PMC_17467060","title":"Soluble HLA-G and control of angiogenesis.","date":"2007","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17467060","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9184910","id":"PMC_9184910","title":"HLA-G functions as a restriction element and a transplantation antigen in mice.","date":"1997","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9184910","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26116450","id":"PMC_26116450","title":"Hypermethylation of the HLA-G promoter is associated with preeclampsia.","date":"2015","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/26116450","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23534973","id":"PMC_23534973","title":"Maternal asthma and microRNA regulation of soluble HLA-G in the airway.","date":"2013","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23534973","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33737343","id":"PMC_33737343","title":"First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33737343","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11137211","id":"PMC_11137211","title":"Modulation of HLA-G antigens expression in myelomonocytic cells.","date":"2000","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11137211","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15722570","id":"PMC_15722570","title":"HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract.","date":"2005","source":"International journal of gastrointestinal cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15722570","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36768880","id":"PMC_36768880","title":"HLA-G and Recurrent Pregnancy Loss.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36768880","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31489189","id":"PMC_31489189","title":"Intercellular transfer of HLA-G: its potential in cancer immunology.","date":"2019","source":"Clinical & translational immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31489189","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14708714","id":"PMC_14708714","title":"Hide-and-seek in the brain: a role for HLA-G mediating immune privilege for glioma cells.","date":"2003","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/14708714","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18494931","id":"PMC_18494931","title":"Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia.","date":"2008","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18494931","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32680723","id":"PMC_32680723","title":"Fetal HLA-G mediated immune tolerance and interferon response in preeclampsia.","date":"2020","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/32680723","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20814356","id":"PMC_20814356","title":"Expression of soluble HLA-G identifies favorable outcomes in liver transplant recipients.","date":"2010","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/20814356","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10092547","id":"PMC_10092547","title":"How do NK cells sense the expression of HLA-G class Ib molecules?","date":"1999","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/10092547","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11091213","id":"PMC_11091213","title":"Aberrant expression of HLA-G antigen in interferon gamma-stimulated acute myelogenous leukaemia.","date":"2000","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/11091213","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35237271","id":"PMC_35237271","title":"Role of HLA-G in Viral Infections.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35237271","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20356631","id":"PMC_20356631","title":"Interaction between HLA-G and monocyte/macrophages in human pregnancy.","date":"2010","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20356631","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16441481","id":"PMC_16441481","title":"HLA-G levels in serum and plasma.","date":"2006","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/16441481","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23752205","id":"PMC_23752205","title":"Synthetic HLA-G proteins for therapeutic use in transplantation.","date":"2013","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/23752205","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22931388","id":"PMC_22931388","title":"New insights into HLA-G and inflammatory diseases.","date":"2012","source":"Inflammation & allergy drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/22931388","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23238216","id":"PMC_23238216","title":"NK cytolysis is dependent on the proportion of HLA-G expression.","date":"2012","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23238216","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12681364","id":"PMC_12681364","title":"Analysis of HLA-G expression in malignant hematopoetic cells from leukemia patients.","date":"2003","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/12681364","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17689098","id":"PMC_17689098","title":"HLA-G expression in malignant melanoma.","date":"2007","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/17689098","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10228553","id":"PMC_10228553","title":"Immunotolerant functions of HLA-G.","date":"1999","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/10228553","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11726606","id":"PMC_11726606","title":"Uveal melanoma: no expression of HLA-G.","date":"2001","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/11726606","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11137217","id":"PMC_11137217","title":"Analysis of the role of HLA-G in preeclampsia.","date":"2000","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11137217","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16330473","id":"PMC_16330473","title":"Does 'soluble' HLA-G really exist? Another twist to the tale.","date":"2005","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/16330473","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38310272","id":"PMC_38310272","title":"Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects.","date":"2024","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38310272","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33745758","id":"PMC_33745758","title":"Role of the HLA-G immune checkpoint molecule in pregnancy.","date":"2021","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33745758","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35185887","id":"PMC_35185887","title":"Roles of HLA-G/KIR2DL4 in Breast Cancer Immune Microenvironment.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35185887","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32670296","id":"PMC_32670296","title":"The Role of HLA-G in Human Papillomavirus Infections and Cervical Carcinogenesis.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32670296","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23002136","id":"PMC_23002136","title":"LINE1 family member is negative regulator of HLA-G expression.","date":"2012","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/23002136","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15380940","id":"PMC_15380940","title":"Hypoxia does not reduce HLA-G expression on extravillous cytotrophoblasts.","date":"2004","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15380940","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8988550","id":"PMC_8988550","title":"HLA-G transcription studies during the different stages of normal and malignant hematopoiesis.","date":"1996","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/8988550","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2326636","id":"PMC_2326636","title":"A class I antigen, HLA-G, expressed in human trophoblasts.","date":"1990","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/2326636","citation_count":1219,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8612235","id":"PMC_8612235","title":"Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein.","date":"1996","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8612235","citation_count":874,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17932417","id":"PMC_17932417","title":"Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells.","date":"2007","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/17932417","citation_count":798,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17353931","id":"PMC_17353931","title":"Large-scale mapping of human protein-protein interactions by mass spectrometry.","date":"2007","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/17353931","citation_count":733,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10190900","id":"PMC_10190900","title":"A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells.","date":"1999","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10190900","citation_count":559,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33845483","id":"PMC_33845483","title":"Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/33845483","citation_count":532,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3480534","id":"PMC_3480534","title":"A human major histocompatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment.","date":"1987","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3480534","citation_count":476,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1570318","id":"PMC_1570318","title":"Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1570318","citation_count":465,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20448110","id":"PMC_20448110","title":"Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20448110","citation_count":459,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12853576","id":"PMC_12853576","title":"Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12853576","citation_count":448,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9531263","id":"PMC_9531263","title":"Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9531263","citation_count":430,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9539768","id":"PMC_9539768","title":"HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9539768","citation_count":380,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10843658","id":"PMC_10843658","title":"Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10843658","citation_count":366,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2295808","id":"PMC_2295808","title":"Human trophoblast and the choriocarcinoma cell line BeWo express a truncated HLA Class I molecule.","date":"1990","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2295808","citation_count":360,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10330285","id":"PMC_10330285","title":"IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes.","date":"1999","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10330285","citation_count":354,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14602228","id":"PMC_14602228","title":"The 14 bp deletion-insertion polymorphism in the 3' UT region of the HLA-G gene influences HLA-G mRNA stability.","date":"2003","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14602228","citation_count":325,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9586638","id":"PMC_9586638","title":"Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules.","date":"1998","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9586638","citation_count":325,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11463741","id":"PMC_11463741","title":"Structure--function relationships in HIV-1 Nef.","date":"2001","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/11463741","citation_count":317,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9144223","id":"PMC_9144223","title":"The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors?","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9144223","citation_count":315,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18249584","id":"PMC_18249584","title":"HLA-G: from biology to clinical benefits.","date":"2008","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18249584","citation_count":305,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9933109","id":"PMC_9933109","title":"The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells.","date":"1999","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9933109","citation_count":300,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11290782","id":"PMC_11290782","title":"HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11290782","citation_count":286,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18334671","id":"PMC_18334671","title":"Beyond the increasing complexity of the immunomodulatory HLA-G molecule.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18334671","citation_count":276,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":40511,"output_tokens":5850,"usd":0.104641},"stage2":{"model":"claude-opus-4-6","input_tokens":9456,"output_tokens":4256,"usd":0.23052},"total_usd":0.706098,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":52546,"output_tokens":7290,"usd":0.133494},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":11244,"output_tokens":4083,"usd":0.237443}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"HLA-G protein expression is restricted to differentiated invasive cytotrophoblasts at the maternal-fetal interface, and is upregulated as cytotrophoblast stem cells differentiate along the invasive pathway in vitro, establishing a direct link between HLA-G expression and trophoblast differentiation.\",\n      \"method\": \"Immunoaffinity purification, monoclonal antibody staining of tissue sections, in vitro differentiation assays, RT-PCR\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (immunoaffinity purification, IHC, in vitro differentiation, RT-PCR), foundational paper with 383 citations\",\n      \"pmids\": [\"7706718\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"HLA-G molecules present peptides derived from cellular proteins in the same manner as classical HLA molecules, with a specific peptide-binding motif (XI/LPXXXXXL) featuring anchor residues at positions 2 (Ile/Leu), 3 (Pro), and 9 (Leu); peptide-binding assays showed two of three anchor residues are sufficient for binding.\",\n      \"method\": \"Peptide extraction from stably transfected LCL721.221 cells, individual and pool sequencing, peptide-binding assays\",\n      \"journal\": \"Current biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct biochemical reconstitution with peptide sequencing and binding assays, 170 citations\",\n      \"pmids\": [\"8805247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"HLA-G has severely reduced spontaneous endocytosis compared to classical MHC class I proteins, due to its short cytoplasmic tail; chimeric proteins bearing the HLA-G C-terminal sequence or GPI-tailed HLA-C also showed impaired internalization.\",\n      \"method\": \"Surface biotinylation, endocytosis assays with fluorescent beta2-microglobulin mutant (Ser88Cys), chimeric protein analysis in B cell transfectants\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstitution with chimeric proteins and non-perturbative fluorescent labeling method, mechanistic link established\",\n      \"pmids\": [\"9368631\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"HLA-G is a ligand for inhibitory receptors ILT2 (LIR1), ILT4, and p49 on NK and other immune cells; NK recognition of HLA-G1-expressing cells involves direct ILT2 engagement by HLA-G1, and indirect recognition via CD94/NKG2A and CD94/NKG2C receptors binding HLA-E loaded with the VMAPRTLFL nonamer derived from the HLA-G leader sequence.\",\n      \"method\": \"NK cell cytotoxicity assays, receptor-ligand binding studies\",\n      \"journal\": \"Immunological reviews\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor-ligand interaction studies replicated across labs, supported by multiple functional assays\",\n      \"pmids\": [\"10319265\", \"10092547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Membrane-bound HLA-G1 and HLA-G2 isoforms expressed on transfected cells inhibit NK cell cytolysis and T cell allogeneic proliferative responses; full-length soluble HLA-G also inhibits NK and T cell functions.\",\n      \"method\": \"Transfected cell lines (HLA-G1, HLA-G2), NK cytotoxicity assays, T cell allogeneic proliferation assays\",\n      \"journal\": \"Seminars in cancer biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional inhibition demonstrated with transfected cell lines, replicated across multiple effector cell types\",\n      \"pmids\": [\"10092545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Soluble HLA-G is present in plasma and amniotic fluid as two molecular variants corresponding to HLA-G1 (35 kDa) and HLA-G2 (27 kDa) isoforms, measurable by a two-step ELISA that depletes classical HLA class I antigens.\",\n      \"method\": \"Two-step ELISA, SDS-PAGE analysis of plasma\",\n      \"journal\": \"Tissue antigens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical identification of soluble isoforms in body fluids with validated assay\",\n      \"pmids\": [\"10082427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"HLA-G truncated isoforms (G2, G3, G4), in addition to HLA-G1, are translated into proteins in first-trimester cytotrophoblast cells and can inhibit NK cytolysis, demonstrating that all membrane-bound isoforms contribute to immune privilege.\",\n      \"method\": \"Western blot of cytotrophoblast cells, NK cytolysis assays using target cells transfected with HLA-G genomic DNA\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — protein expression confirmed in primary cells, functional NK inhibition demonstrated for each isoform\",\n      \"pmids\": [\"11137216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"HLA-G forms disulfide-linked dimers on the cell surface via Cys-42 in the alpha1 domain; mutation of Cys-42 to serine completely abrogates dimerization, suggesting this residue is exclusively responsible for the disulfide linkage.\",\n      \"method\": \"Immunoprecipitation from surface-biotinylated transfectants, DTT reduction, site-directed mutagenesis (Cys42Ser)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis identifies specific residue, combined with biochemical pulldown and reduction experiments\",\n      \"pmids\": [\"12454284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Melanoma-derived exosomes bearing membrane-bound HLA-G1 are released by HLA-G-positive melanoma cells and by HLA-G-negative cells transfected with HLA-G1 cDNA, providing a mechanism by which tumor cells can disseminate tolerogenic HLA-G molecules.\",\n      \"method\": \"Exosome purification by sucrose gradient, Western blotting, flow cytometry\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biochemical purification of exosomes confirmed by multiple methods, functional implication inferred\",\n      \"pmids\": [\"14602237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"HLA-G modulates immune responses through multiple receptor interactions: HLA-G1 inhibits NK- and T-cell-mediated lysis via ILT2 and ILT4; KIR2DL4 engagement triggers different reactions depending on activation state; HLA-G5 binds CD8 and induces Fas/FasL-mediated apoptosis in activated CD8+ lymphocytes.\",\n      \"method\": \"NK cytotoxicity assays, receptor binding studies, apoptosis assays\",\n      \"journal\": \"Seminars in cancer biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — functional receptor-ligand interaction data from multiple effector cell types, CD8/Fas mechanism reported\",\n      \"pmids\": [\"14708711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Soluble HLA-G can be generated by metalloproteinase-dependent proteolytic shedding of membrane-bound HLA-G1 at the post-translational level; the shed soluble HLA-G1 associates with beta2-microglobulin, contains bound peptides stable at physiological conditions, and protects HLA class I-negative K562 cells from NK lysis.\",\n      \"method\": \"Metalloproteinase inhibitor treatment, immunoprecipitation, NK cell cytotoxicity assay with K562 targets\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mechanistic shedding pathway identified with inhibitors, functional validation by NK lysis assay\",\n      \"pmids\": [\"14697234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"HLA-G-ILT4 interaction on dendritic cells induces tolerogenic DC with arrested maturation/activation, which in turn differentiate anergic and immunosuppressive CD4+ and CD8+ T cells; ILT4 ligation disrupts MHC class II antigen presentation pathway and prolongs allograft survival in ILT4-transgenic mice.\",\n      \"method\": \"Human monocyte-derived DC cultures, ILT4-transgenic mouse model, gene expression profiling, allograft survival assay\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including transgenic in vivo model, gene expression, and functional T cell assays\",\n      \"pmids\": [\"15770701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Residues Met76 and Gln79 in the HLA-G alpha1 domain are critical for KIR2DL4 recognition; mutation of these residues to Ala76,79 reduces KIR2DL4-IgG Fc fusion protein binding affinity and alters KIR2DL4-transfected NK-92 cell cytolysis against HLA-G-expressing K562 targets.\",\n      \"method\": \"Retroviral transduction, KIR2DL4-IgG Fc fusion protein binding assay, NK cytotoxicity assay, site-directed mutagenesis\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis identifies specific binding residues, validated by functional cytolysis assay\",\n      \"pmids\": [\"15780179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Neuronotropic viruses (rabies virus and HSV-1) upregulate HLA-G isoform expression in infected neurons and neighboring uninfected cells; IFN-beta and IFN-gamma can upregulate HLA-G expression in uninfected cells; RABV induces predominantly HLA-G1, HSV-1 induces HLA-G3 and HLA-G5.\",\n      \"method\": \"In vitro neuron infection, cytokine treatment, flow cytometry, Western blot, RT-PCR\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct infection experiments with multiple detection methods, mechanistic role of secreted IFNs identified\",\n      \"pmids\": [\"16306594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Soluble HLA-G1 (HLA-G5) inhibits endothelial cell proliferation, migration and tubule formation through binding to the CD160 receptor via an apoptotic pathway, and blocks in vivo corneal neoangiogenesis in rabbit.\",\n      \"method\": \"In vitro endothelial cell proliferation, migration and tubule formation assays, CD160 receptor binding, in vivo rabbit corneal angiogenesis model\",\n      \"journal\": \"Journal of reproductive immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — receptor identified (CD160), mechanism (apoptosis) established, validated in vivo\",\n      \"pmids\": [\"17467060\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"A SNP in the 3' UTR of HLA-G at position +3142 influences allele-specific targeting of three microRNAs (miR-148a, miR-148b, miR-152 family) to this gene, providing a post-transcriptional regulatory mechanism affecting HLA-G expression.\",\n      \"method\": \"Genetic association analysis, miRNA target prediction and functional validation\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — miRNA-SNP interaction identified, mechanistic validation of allele-specific targeting shown\",\n      \"pmids\": [\"17847008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"HLA-G induces suppressor cells via two distinct processes: (i) differentiation of naive T cells into lasting suppressor T cells, and (ii) rapid transfer of HLA-G from APC or tumor cells to T or NK cells (trogocytosis), converting them into temporary HLA-G-positive suppressor cells.\",\n      \"method\": \"T cell differentiation assays, trogocytosis (membrane transfer) assays, functional suppression assays\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — two distinct mechanisms identified with functional assays, trogocytosis mechanism described\",\n      \"pmids\": [\"18817832\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"KIR2DL4, the only known receptor for HLA-G, resides in endosomes (not on the cell surface as other KIRs); soluble HLA-G accumulates in KIR2DL4+ endosomes and signals from this intracellular site for proinflammatory and proangiogenic cytokine/chemokine secretion (not cytotoxicity), using a novel endosomal signaling pathway involving DNA-PKcs and Akt serine/threonine kinases.\",\n      \"method\": \"Subcellular fractionation, endosomal localization studies, signaling pathway analysis, cytokine/chemokine secretion assays\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — novel endosomal localization and signaling mechanism described with direct localization experiments and kinase identification\",\n      \"pmids\": [\"22934097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"HLA-G interaction with ILT2 on malignant B cells mediates negative signaling that inhibits B cell proliferation, demonstrating an antitumor activity of HLA-G distinct from its protumorigenic role in solid tumors.\",\n      \"method\": \"B cell proliferation assays, ILT2 receptor blocking/signaling experiments\",\n      \"journal\": \"Journal of immunology research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — functional proliferation inhibition via defined receptor (ILT2) demonstrated\",\n      \"pmids\": [\"24800261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NK cell cytolysis is inhibited by HLA-G1 in a proportion-dependent manner (r=0.925), establishing a quantitative relationship between HLA-G1 expression level on tumor cells and degree of NK cell inhibition.\",\n      \"method\": \"NK cytotoxicity assay (CD107a surface expression), varying proportions of HLA-G1-expressing K562 cells\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — quantitative functional relationship established in vitro\",\n      \"pmids\": [\"23238216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Synthetic HLA-G-derived polypeptides (alpha3-L)x2 and (alpha1-alpha3)x2 bind the HLA-G receptor LILRB2 (ILT4) and are functionally tolerogenic in vivo; a single treatment with (alpha1-alpha3)x2 significantly prolonged skin allograft survival in mice, and four weekly treatments induced complete tolerance.\",\n      \"method\": \"LILRB2 binding assays, in vivo murine skin allograft model, in vitro tumor cell proliferation inhibition\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — receptor binding confirmed, in vivo functional validation with dose-response, mechanistic link established\",\n      \"pmids\": [\"23752205\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"KIR2DL4-HLA-G interactions induce cellular senescence in NK cells, and the resulting senescence-associated secretory phenotype (SASP) promotes vascular remodeling, providing a molecular mechanism linking HLA-G signaling to spiral artery remodeling during early pregnancy.\",\n      \"method\": \"NK cell senescence assays, SASP characterization, KIR2DL4 signaling studies\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — mechanistic pathway (KIR2DL4→senescence→SASP→vascular remodeling) described with functional assays\",\n      \"pmids\": [\"24998350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DNMT-1-mediated promoter hypermethylation of the HLA-G gene represses its expression; both treatment with the DNMT inhibitor 5-aza-2'-deoxycytidine and specific siRNA knockdown of DNMT-1 significantly increase HLA-G expression in trophoblast cells.\",\n      \"method\": \"Bisulfite pyrosequencing, immunohistochemistry, qPCR, DNMT inhibitor treatment, siRNA knockdown in trophoblast cell line\",\n      \"journal\": \"Molecular human reproduction\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — epigenetic writer (DNMT-1) identified with both pharmacologic and genetic loss-of-function confirming mechanism\",\n      \"pmids\": [\"26116450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"HLA-G+ EVT interaction with decidual CD4+ T cells increases the number of CD4+CD25hiFOXP3+CD45RA+ resting regulatory T cells and upregulates FOXP3 expression, establishing a direct cellular mechanism by which HLA-G+ trophoblasts promote maternal immune tolerance.\",\n      \"method\": \"Purified HLA-G+ EVT cocultures with sample-matched decidual NK cells, macrophages, CD4+ and CD8+ T cells; flow cytometry; microarray gene expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — highly purified primary cells, multiple cell type cocultures, functional Treg induction confirmed\",\n      \"pmids\": [\"26015573\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A cis-regulatory enhancer element (Enhancer L) located 12 kb upstream of HLA-G controls trophoblast-specific HLA-G expression through long-range chromatin looping to the HLA-G promoter; CRISPR/Cas9 deletion of Enhancer L abolishes HLA-G expression in JEG3 cells and primary trophoblasts. CEBP and GATA family transcription factors bind Enhancer L motifs essential for placentation and regulate HLA-G expression.\",\n      \"method\": \"Massively parallel reporter assay (MPRA), CRISPR/Cas9 deletion, RNA-seq, DNase-seq, chromatin conformation capture (3C), transcription factor ChIP\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — CRISPR loss-of-function, 3C chromatin looping, MPRA mutagenesis, and TF binding converge on same mechanism\",\n      \"pmids\": [\"27078102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"A LINE1 element upstream of HLA-G acts as a negative regulator of HLA-G expression; silencing of HLA-G involves a DNA secondary structure generated within the LINE1 sequence, contributing to the restricted tissue-specific expression of HLA-G.\",\n      \"method\": \"Human artificial chromosome system with single-copy genomic DNA manipulation, functional reporter assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — single-copy genomic manipulation identifies LINE1 as cis-regulatory silencer with mechanistic DNA secondary structure evidence\",\n      \"pmids\": [\"23002136\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HLA-G is a nonclassical MHC class I molecule that forms disulfide-linked dimers via Cys-42 on the cell surface, is expressed specifically in invasive trophoblasts (controlled by a distant enhancer via chromatin looping involving CEBP/GATA transcription factors and repressed by DNMT-1 methylation and a LINE1 silencer), presents peptides with a specific binding motif, inhibits NK cell cytotoxicity and T cell responses by engaging inhibitory receptors ILT2, ILT4, and KIR2DL4 (the latter signaling from endosomes via DNA-PKcs/Akt to drive proangiogenic/proinflammatory cytokine secretion and NK senescence), induces tolerogenic dendritic cells and regulatory T cells through ILT4 ligation, can be shed from the cell surface by metalloproteinases or released via exosomes, and indirectly activates CD94/NKG2 receptors by supplying the VMAPRTLFL leader-sequence peptide to HLA-E.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1987,\n      \"finding\": \"HLA-G (originally designated HLA-6.0) was identified as a non-HLA-A/B/C class I gene encoding a protein with a shortened cytoplasmic segment due to an in-frame stop codon that truncates the majority of the cytoplasmic tail, structurally resembling murine Qa-region class I genes.\",\n      \"method\": \"Genomic cloning, sequencing, and structural analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original structural characterization by sequencing with functional domain analysis; foundational paper\",\n      \"pmids\": [\"3480534\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"HLA-G protein is expressed as an array of five 37–39 kDa isoforms on first-trimester villous cytotrophoblasts and is greatly reduced in third-trimester cytotrophoblasts; it is not expressed in normal lymphoid cells, demonstrating cell-type-specific and developmental regulation.\",\n      \"method\": \"Two-dimensional gel electrophoresis, immunoprecipitation\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct protein detection by 2D-PAGE with biochemical characterization; foundational paper with high citations\",\n      \"pmids\": [\"2326636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"HLA-G encodes a truncated HLA class I heavy chain (~40 kDa) expressed on extravillous trophoblast and the choriocarcinoma cell line BeWo, confirmed by cDNA cloning and sequencing showing high homology to HLA-6.0 genomic clone.\",\n      \"method\": \"cDNA cloning, sequencing, RT-PCR, immunoprecipitation\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cDNA cloning and protein immunoprecipitation; replicated findings from independent lab\",\n      \"pmids\": [\"2295808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"The HLA-G primary transcript is alternatively spliced to yield at least three distinct mature mRNAs encoding proteins resembling class I (full-length) and truncated forms (lacking alpha2 domain alone, or alpha2+alpha3 domains), with three corresponding protein products detected by immunoprecipitation.\",\n      \"method\": \"RT-PCR, sequencing of alternatively spliced transcripts, immunoprecipitation of [35S]methionine-labeled proteins\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical characterization of alternative splice isoforms with protein-level confirmation\",\n      \"pmids\": [\"1570318\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"HLA-G protein expression is restricted to invasive cytotrophoblasts at the maternal-fetal interface and is up-regulated as cytotrophoblast stem cells differentiate along the invasive pathway in vitro, with term cytotrophoblasts (reduced invasive capacity) showing decreased HLA-G up-regulation.\",\n      \"method\": \"mAb generation using synthetic alpha1-domain peptide, immunoaffinity purification, immunohistochemistry on tissue sections, Northern blot\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct protein detection with custom mAbs, functional differentiation assay, replicated by multiple methods\",\n      \"pmids\": [\"7706718\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"HLA-G molecules present peptides in a manner analogous to classical HLA molecules; the HLA-G peptide motif is defined as XI/LPXXXXXL with anchor residues at positions 2 (Ile/Leu), 3 (Pro), and 9 (Leu), and peptide-binding assays showed two of three anchors are sufficient for binding.\",\n      \"method\": \"Peptide elution from stably transfected LCL721.221 cells, individual and pool sequencing, peptide-binding assay\",\n      \"journal\": \"Current biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct biochemical peptide elution and sequencing with binding assay validation\",\n      \"pmids\": [\"8805247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Both HLA-G1 (full-length) and HLA-G2 (alpha1+alpha3 truncation) inhibit NK cell cytolysis; HLA-G2 is present at the cell surface associated with beta2-microglobulin; the alpha1 domain shared by G1 and G2 mediates protection from NK lysis; HLA-G was proposed as a 'public ligand' for NK inhibitory receptors.\",\n      \"method\": \"Stable transfection of K562 cells with HLA-G1 or HLA-G2 cDNA, NK cytolysis assay with polyclonal NK cells from 20 donors, mAb blocking\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional transfection experiments with blocking antibodies, replicated across 20 donors\",\n      \"pmids\": [\"9144223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The impaired spontaneous endocytosis of HLA-G is caused by its short cytoplasmic tail; chimeric proteins carrying the HLA-G cytoplasmic tail (or GPI-anchored HLA-C) were not efficiently internalized, demonstrating that the truncated cytoplasmic tail of HLA-G is responsible for its prolonged cell-surface residence.\",\n      \"method\": \"Surface biotinylation, flow cytometric endocytosis assay, beta2-microglobulin exchange labeling with Texas red, chimeric protein constructs\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods including chimeric constructs and non-perturbative labeling approach\",\n      \"pmids\": [\"9368631\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"ILT4 (expressed on monocytes, macrophages, and dendritic cells) binds both classical MHC class I molecules and the nonclassical HLA-G, transducing inhibitory signals via immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that recruit phosphatases and suppress early activation signaling in myelomonocytic cells.\",\n      \"method\": \"Receptor characterization by binding assays, ITIM-mediated signaling assay, transfection\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct receptor-ligand binding and downstream signaling characterization\",\n      \"pmids\": [\"9531263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Soluble KIR2DL4 binds specifically to cells expressing HLA-G but not to cells expressing other HLA class I molecules; KIR2DL4 is expressed on all NK cells (unlike other clonally distributed KIRs); functional transfer of KIR2DL4 into NK-92 cells inhibits lysis of HLA-G+ targets but not HLA-E+ targets.\",\n      \"method\": \"Recombinant soluble KIR2DL4 binding assay, flow cytometry, functional NK cytotoxicity assay with KIR2DL4 transfectants\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — recombinant protein binding assay combined with functional transfer experiment; highly cited foundational paper\",\n      \"pmids\": [\"10190900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"NK recognition of HLA-G1 involves two non-overlapping receptor-ligand systems: (1) direct engagement of ILT2 (LIR1) by HLA-G1, and (2) CD94/NKG2A interaction with HLA-E co-expressed via binding to the nonamer peptide (VMAPRTLFL) from the HLA-G leader sequence.\",\n      \"method\": \"HLA-E-negative mutant transfectants (site-directed mutagenesis of HLA-G leader sequence), ILT2-Ig fusion protein binding assay, mAb blocking of CD94/NKG2A and ILT2\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis of leader sequence to ablate HLA-E induction, combined with receptor-specific blocking\",\n      \"pmids\": [\"9933109\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"IL-10 selectively induces HLA-G gene transcription in trophoblasts and up-regulates HLA-G surface expression in peripheral blood monocytes, while simultaneously down-regulating classical MHC class I and MHC class II on monocytes, suggesting IL-10 as a tissue-specific activator of HLA-G expression at the fetal-maternal interface.\",\n      \"method\": \"Northern blot, RNase protection assay, RT-PCR, flow cytometry in trophoblast cultures and monocytes\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods; selective effect on HLA-G vs. classical HLA shown in same system\",\n      \"pmids\": [\"10330285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Soluble HLA-G1 (sHLA-G1) triggers apoptosis in activated (but not resting) CD8+ peripheral blood cells through the CD95/CD95 ligand pathway; sHLA-G1 enhances CD95 ligand expression in activated CD8+ cells; this apoptosis depends on the interaction of sHLA-G1 with CD8 molecules, as CD8-specific mAbs block cell death.\",\n      \"method\": \"Affinity-purified sHLA-G1, Western blotting for CD95L, CD95-Fc and ZB4 blocking experiments, CD8 mAb blocking\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical purification with multiple blocking experiments defining the molecular pathway\",\n      \"pmids\": [\"10843658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"HLA-G2, -G3, and -G4 truncated isoforms reach the cell surface as endoglycosidase H-sensitive (immature) glycoproteins and protect transfected cells from both NK and CTL cytolysis, demonstrating that non-G1 membrane-bound isoforms are functional immunomodulatory molecules.\",\n      \"method\": \"Stable transfection, endoglycosidase H sensitivity assay, NK and CTL cytotoxicity assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct functional NK/CTL assays combined with glycosylation analysis of surface isoforms\",\n      \"pmids\": [\"11290782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"HLA-G forms disulfide-linked dimers on the cell surface via a disulfide bond exclusively through Cys-42; mutation of Cys-42 to serine completely abrogates dimerization; the ~78 kDa dimer is reduced to ~39 kDa by DTT.\",\n      \"method\": \"Surface biotinylation, immunoprecipitation with anti-beta2m mAb, DTT reduction, site-directed mutagenesis (Cys42Ser)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis identifying the specific cysteine residue responsible, combined with biochemical verification\",\n      \"pmids\": [\"12454284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ILT2 and ILT4 bind HLA-G with 3- to 4-fold higher affinity than classical MHC class I molecules (KD values measured by surface plasmon resonance); ILT2 binds with 2- to 3-fold higher affinity than ILT4 to the same MHCI; ILT2 and ILT4 compete with CD8 for MHC class I binding.\",\n      \"method\": \"Surface plasmon resonance (SPR) with soluble ILT2 and ILT4 proteins against multiple MHC class I molecules; CD8 competition assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — quantitative biophysical binding measurements with defined recombinant proteins\",\n      \"pmids\": [\"12853576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Melanoma cells release exosomes bearing HLA-G1; these HLA-G1-positive exosomes are also secreted by HLA-G-negative melanoma cells transfected with HLA-G1 cDNA, providing a mechanism for tumor immune modulation via secreted vesicles.\",\n      \"method\": \"Sucrose gradient ultracentrifugation, Western blotting, flow cytometry of purified exosomes\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical purification and characterization of exosomes; single lab\",\n      \"pmids\": [\"14602237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"HLA-G1 inhibits NK- and CTL-mediated lysis via ILT2 and ILT4; HLA-G5 (soluble) binds CD8 and induces Fas/FasL-mediated apoptosis in activated CD8+ lymphocytes; KIR2DL4 engagement triggers different responses depending on effector cell activation state.\",\n      \"method\": \"Functional cytotoxicity assays, receptor-ligand characterization\",\n      \"journal\": \"Seminars in cancer biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — review synthesizing experimental findings; individual mechanistic findings supported by primary papers already cited\",\n      \"pmids\": [\"14708711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Soluble HLA-G1 can be generated by metalloproteinase-dependent shedding of membrane-bound HLA-G1 at the post-translational level; shed sHLA-G1 associates with beta2-microglobulin, contains bound peptides stable at physiological conditions, and protects HLA class I-negative K562 cells from NK lysis.\",\n      \"method\": \"Metalloproteinase inhibitor experiments, Western blotting, NK cytotoxicity assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological inhibitor defining mechanism of shedding with functional NK lysis readout; single lab\",\n      \"pmids\": [\"14697234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"HLA-G binding to ILT4 on dendritic cells induces tolerogenic DC with arrested maturation/activation; HLA-G-modified DCs induce anergic and immunosuppressive CD4+ and CD8+ T cells; ILT4 ligation on DCs disrupts MHC class II antigen presentation pathway and significantly prolongs allograft survival in ILT4-transgenic mice.\",\n      \"method\": \"Human monocyte-derived DC assays, ILT4-transgenic mouse model, gene expression profiling, allograft survival experiments\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro human DC system combined with in vivo transgenic mouse allograft model with functional readouts\",\n      \"pmids\": [\"15770701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Residues Met76 and Gln79 in the alpha1 domain of HLA-G are critical for KIR2DL4 recognition; mutation of these residues to Ala reduces binding of KIR2DL4-IgG Fc fusion protein to HLA-G and alters KIR2DL4-transfected NK-92 cell cytolysis against HLA-G-expressing targets.\",\n      \"method\": \"Retroviral transduction, KIR2DL4-IgG Fc fusion protein binding assay, NK cytotoxicity assay with KIR2DL4-transfected NK-92 cells\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — site-directed mutagenesis with functional binding and cytolysis assays; single lab\",\n      \"pmids\": [\"15780179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MSCs secrete the soluble isoform HLA-G5 in an IL-10-dependent manner; cell contact between MSCs and allostimulated T cells is required for full HLA-G5 secretion; blocking HLA-G5 with neutralizing antibody reveals it suppresses allogeneic T-cell proliferation, expands CD4+CD25highFOXP3+ regulatory T cells, inhibits NK-mediated cytolysis, and inhibits IFN-gamma secretion by NK cells.\",\n      \"method\": \"Neutralizing anti-HLA-G antibody blocking, IL-10 pathway inhibition, flow cytometry, cytotoxicity assays\",\n      \"journal\": \"Stem cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional readouts with specific antibody blocking; highly cited paper replicating HLA-G5 function\",\n      \"pmids\": [\"17932417\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Tr1 cell differentiation by DC-10 (IL-10-producing tolerogenic DCs that express ILT4 and HLA-G) is IL-10-dependent and requires the ILT4/HLA-G signaling pathway; DC-10 induce antigen-specific IL-10-producing Tr1 cells through this pathway.\",\n      \"method\": \"DC-10 isolation from peripheral blood and in vitro differentiation, Tr1 induction assays, pathway blocking experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — specific pathway blocking with functional T-cell differentiation readout; highly cited paper\",\n      \"pmids\": [\"20448110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"KIR2DL4 resides in endosomes (not on the cell surface like other KIRs); soluble HLA-G accumulates in KIR2DL4+ endosomes; KIR2DL4 signals from this intracellular site for a proinflammatory and proangiogenic response using a novel endosomal signaling pathway involving serine/threonine kinases DNA-PKcs and Akt.\",\n      \"method\": \"Subcellular localization studies, endosomal fractionation, kinase pathway analysis\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — subcellular localization with defined signaling pathway identification; review citing primary experimental work\",\n      \"pmids\": [\"22934097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Two synthetic HLA-G-derived molecules—(α3-L)x2 and (α1-α3)x2 polypeptides—bind the HLA-G receptor LILRB2; (α1-α3)x2 prolongs allograft survival in mice (one treatment significantly prolongs, four weekly treatments induce complete tolerance) and inhibits tumor cell line proliferation as does full-length HLA-G.\",\n      \"method\": \"Receptor binding assay with LILRB2, in vivo murine skin allograft model, in vitro tumor proliferation assay\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — recombinant protein binding combined with in vivo functional validation in allograft model\",\n      \"pmids\": [\"23752205\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"HLA-G interaction with HLA-G+ extravillous trophoblasts (EVT) and decidual CD4+ T cells results in increased numbers of CD4+CD25hiIFOXP3+CD45RA+ resting regulatory T cells (Tregs) and increased FOXP3 expression, providing a mechanism by which EVT maintain fetal-maternal tolerance.\",\n      \"method\": \"Purification of primary HLA-G+ EVT by FACS, coculture assays with decidual NK cells, macrophages, CD4+ and CD8+ T cells; microarray gene expression analysis; flow cytometry\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — highly purified primary cell cocultures with functional Treg induction readout and gene expression profiling\",\n      \"pmids\": [\"26015573\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A trophoblast-specific cis-regulatory enhancer (Enhancer L) located 12 kb upstream of HLA-G controls tissue-specific HLA-G expression; CRISPR/Cas9-mediated deletion of Enhancer L ablates HLA-G expression in JEG3 cells and primary human trophoblasts; Enhancer L loops into the HLA-G promoter via chromatin conformation capture; CEBP and GATA family transcription factors bind Enhancer L and regulate HLA-G expression.\",\n      \"method\": \"Massively parallel reporter assay (MPRA), CRISPR/Cas9 deletion, RNA-seq, DNase-seq, chromatin conformation capture (3C), saturation mutagenesis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal genomic and editing methods with functional validation in primary cells\",\n      \"pmids\": [\"27078102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The 14 bp insertion polymorphism in the 3' UTR of HLA-G generates an additional splice that removes 92 bases from exon 8; HLA-G mRNAs with this 92-base deletion are more stable than complete mRNA forms, demonstrating that this region controls post-transcriptional regulation of HLA-G expression.\",\n      \"method\": \"Actinomycin D mRNA stability assays in JEG-3 and transfected M8 melanoma cells, RT-PCR\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct mRNA stability measurement in relevant cell lines; single lab\",\n      \"pmids\": [\"14602228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"A LINE1 sequence upstream of HLA-G functions as a negative regulator of HLA-G gene expression; HLA-G silencing involves a DNA secondary structure generated within the LINE1 element, as shown by manipulation of a single genomic copy on a human artificial chromosome.\",\n      \"method\": \"Human artificial chromosome system with single-copy genomic manipulation, reporter assays, DNA secondary structure analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — single-copy genomic manipulation with functional silencing readout; single lab\",\n      \"pmids\": [\"23002136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DNMT-1-mediated promoter hypermethylation suppresses HLA-G expression; CpG sites in the HLA-G promoter are significantly more methylated in preeclampsia; treatment with DNMT inhibitor 5-aza-2'-deoxycytidine or DNMT-1 siRNA knockdown significantly increases HLA-G expression in a trophoblastic cell line.\",\n      \"method\": \"Bisulfite pyrosequencing, siRNA knockdown, 5-aza-2'-deoxycytidine treatment, qPCR, immunohistochemistry\",\n      \"journal\": \"Molecular human reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and genetic manipulation of DNMT-1 with functional HLA-G expression readout\",\n      \"pmids\": [\"26116450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Soluble HLA-G1 (HLA-G5) inhibits endothelial cell proliferation, migration, and tubule formation through binding to the CD160 receptor via an apoptotic pathway; soluble HLA-G1 also blocks in vivo rabbit corneal neoangiogenesis, demonstrating anti-angiogenic properties.\",\n      \"method\": \"In vitro endothelial cell proliferation, migration and tubule formation assays, CD160 receptor binding, in vivo rabbit corneal neoangiogenesis model\",\n      \"journal\": \"Journal of reproductive immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro receptor-mediated mechanism combined with in vivo functional validation\",\n      \"pmids\": [\"17467060\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HLA-G is a nonclassical MHC class I molecule with a truncated cytoplasmic tail (causing impaired endocytosis and prolonged surface residence) that is alternatively spliced into at least seven isoforms (four membrane-bound, three soluble); it presents peptides via a defined motif (XI/LPXXXXXL), forms disulfide-linked dimers via Cys-42, and exerts immune tolerance by directly binding inhibitory receptors ILT2, ILT4 (with 3–4-fold higher affinity than classical MHC-I), and KIR2DL4 (the latter signaling from endosomes via DNA-PKcs/Akt for proangiogenic responses), inducing tolerogenic DCs, regulatory T cells, and NK senescence, while soluble HLA-G1 triggers CD95/FasL-mediated apoptosis in activated CD8+ T cells via CD8 interaction and inhibits endothelial angiogenesis via CD160; tissue-specific expression in trophoblasts is controlled by a distal enhancer (Enhancer L, 12 kb upstream) looping to the HLA-G promoter via CEBP/GATA transcription factors, with post-transcriptional regulation by 3'UTR 14-bp insertion polymorphism affecting mRNA stability, IL-10-dependent transcriptional induction, LINE1-mediated silencing, and DNMT-1-mediated promoter methylation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"HLA-G is a nonclassical MHC class I molecule that functions as a master immune checkpoint at the maternal-fetal interface and in tumor immune evasion, inhibiting NK cell cytotoxicity, T cell proliferation, and dendritic cell maturation while promoting regulatory T cell differentiation. HLA-G presents peptides with a defined binding motif (XI/LPXXXXXL), forms disulfide-linked dimers via Cys-42, and engages multiple inhibitory receptors—ILT2 and ILT4 on NK, T, and dendritic cells, KIR2DL4 from endosomes via a DNA-PKcs/Akt signaling pathway that drives proangiogenic cytokine secretion and NK senescence, and CD160 on endothelial cells to inhibit angiogenesis through apoptosis [PMID:10319265, PMID:22934097, PMID:17467060, PMID:12454284]. Its trophoblast-restricted expression is controlled by a distant enhancer (Enhancer L) that loops to the HLA-G promoter via CEBP/GATA transcription factors, is repressed by DNMT-1-mediated promoter methylation and a LINE1 silencer element, and is post-transcriptionally regulated by miR-148a/b and miR-152 targeting a 3′UTR SNP [PMID:27078102, PMID:26116450, PMID:23002136, PMID:17847008]. HLA-G also indirectly activates the CD94/NKG2A inhibitory pathway by supplying its VMAPRTLFL leader-sequence peptide to HLA-E, and can disseminate immune tolerance through metalloproteinase-mediated shedding, exosomal release, and trogocytosis-based transfer to effector cells [PMID:10319265, PMID:14697234, PMID:14602237, PMID:18817832].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing that HLA-G expression is restricted to invasive cytotrophoblasts answered where this nonclassical MHC I molecule acts physiologically and linked it to trophoblast differentiation at the maternal-fetal interface.\",\n      \"evidence\": \"Immunoaffinity purification, monoclonal antibody tissue staining, in vitro differentiation, and RT-PCR of human placental cells\",\n      \"pmids\": [\"7706718\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism controlling trophoblast-specific expression unknown\", \"Whether soluble HLA-G isoforms exist in vivo not addressed\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstrating that HLA-G presents peptides with a specific binding motif (XI/LPXXXXXL) established that it functions as a bona fide antigen-presenting molecule despite its limited polymorphism.\",\n      \"evidence\": \"Peptide extraction from HLA-G-transfected cells, pool sequencing, and peptide-binding assays\",\n      \"pmids\": [\"8805247\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological peptide repertoire in trophoblasts not characterized\", \"Whether peptide identity affects receptor engagement unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Showing that HLA-G has severely reduced endocytosis due to its short cytoplasmic tail explained how it maintains prolonged surface expression, a feature critical for sustained immune inhibition.\",\n      \"evidence\": \"Surface biotinylation, endocytosis assays with fluorescent β2m, and chimeric protein analysis in B cell transfectants\",\n      \"pmids\": [\"9368631\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether reduced endocytosis affects peptide loading or exchange unknown\", \"Degradation pathway of HLA-G not defined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identifying ILT2, ILT4, and KIR2DL4 as direct HLA-G receptors, and demonstrating indirect engagement of CD94/NKG2 via HLA-E loaded with the HLA-G leader peptide, defined the receptor repertoire mediating HLA-G's immunosuppressive functions on NK cells, T cells, and dendritic cells.\",\n      \"evidence\": \"NK cytotoxicity assays, receptor-ligand binding studies, T cell proliferation assays, transfected cell lines expressing HLA-G1 and HLA-G2\",\n      \"pmids\": [\"10319265\", \"10092547\", \"10092545\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of HLA-G–receptor interactions not resolved\", \"Relative contribution of each receptor pathway in vivo unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Detecting soluble HLA-G1 and HLA-G2 isoforms in plasma and amniotic fluid established that HLA-G acts systemically, not only as a membrane-bound molecule.\",\n      \"evidence\": \"Two-step ELISA with classical HLA depletion and SDS-PAGE of plasma\",\n      \"pmids\": [\"10082427\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Source cells producing soluble HLA-G not identified\", \"Mechanism of soluble HLA-G generation (shedding vs. secretion) not distinguished\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrating that HLA-G dimerizes via a Cys-42 disulfide bond revealed a unique structural feature among MHC class I molecules that enhances receptor binding avidity.\",\n      \"evidence\": \"Immunoprecipitation from surface-biotinylated transfectants, DTT reduction, Cys42Ser site-directed mutagenesis\",\n      \"pmids\": [\"12454284\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether dimers and monomers differentially engage ILT2/ILT4/KIR2DL4 not quantified\", \"Crystal structure of HLA-G dimer not yet available at this point\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identifying metalloproteinase-dependent shedding and exosomal release as two distinct mechanisms generating soluble HLA-G resolved how HLA-G disseminates immune tolerance beyond direct cell contact.\",\n      \"evidence\": \"Metalloproteinase inhibitor treatment with NK lysis assays; exosome purification by sucrose gradient from melanoma cells\",\n      \"pmids\": [\"14697234\", \"14602237\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the metalloproteinase(s) responsible not determined\", \"Relative contribution of shedding vs. exosomal release in vivo unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showing that HLA-G–ILT4 interaction on dendritic cells arrests DC maturation, generates tolerogenic DCs that induce anergic suppressive T cells, and prolongs allograft survival in vivo established the HLA-G–ILT4 axis as a central tolerogenic pathway.\",\n      \"evidence\": \"Human monocyte-derived DC cultures, ILT4-transgenic mouse model, gene expression profiling, allograft survival assay\",\n      \"pmids\": [\"15770701\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling cascade in DCs upon ILT4 engagement not fully mapped\", \"Whether ILT4 pathway is dominant over ILT2 in DC biology not resolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identifying Met76 and Gln79 as critical residues for KIR2DL4 binding mapped the HLA-G interaction surface for this unique receptor, complementing structural knowledge.\",\n      \"evidence\": \"Site-directed mutagenesis with KIR2DL4-Fc binding assays and NK-92 cytotoxicity assays\",\n      \"pmids\": [\"15780179\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full co-crystal structure of HLA-G–KIR2DL4 not available\", \"Whether other alpha1 residues contribute to binding not exhaustively tested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrating that soluble HLA-G5 inhibits angiogenesis via CD160 receptor binding and apoptosis induction in endothelial cells expanded HLA-G function beyond immunosuppression to vascular biology.\",\n      \"evidence\": \"Endothelial cell proliferation/migration/tubule formation assays, CD160 binding, in vivo rabbit corneal angiogenesis model\",\n      \"pmids\": [\"17467060\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CD160 signaling cascade in endothelial cells not characterized\", \"Relevance to placental vascular remodeling vs. tumor angiogenesis not delineated\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identifying 3′UTR SNP +3142 as a determinant of miR-148a/b and miR-152 targeting provided a post-transcriptional regulatory mechanism that modulates HLA-G expression levels.\",\n      \"evidence\": \"Genetic association analysis with miRNA target prediction and functional validation\",\n      \"pmids\": [\"17847008\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Effect size of miRNA regulation on HLA-G protein levels in trophoblasts not quantified\", \"Whether other 3′UTR polymorphisms contribute not exhaustively tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrating that HLA-G can be transferred from APCs/tumor cells to T/NK cells via trogocytosis, converting recipients into temporary suppressor cells, revealed a cell-contact-dependent mechanism for spreading immune tolerance without requiring new gene expression.\",\n      \"evidence\": \"T cell differentiation assays, trogocytosis (membrane transfer) assays, functional suppression assays\",\n      \"pmids\": [\"18817832\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Duration and stability of trogocytosis-acquired HLA-G on effector cells not defined\", \"In vivo relevance of trogocytosis pathway not demonstrated\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Discovering that KIR2DL4 resides in endosomes and signals via DNA-PKcs/Akt upon soluble HLA-G binding—driving proangiogenic/proinflammatory cytokine secretion rather than cytotoxicity—overturned the assumption that KIR signaling occurs exclusively from the cell surface.\",\n      \"evidence\": \"Subcellular fractionation, endosomal localization studies, signaling pathway analysis, cytokine/chemokine secretion assays\",\n      \"pmids\": [\"22934097\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How HLA-G reaches KIR2DL4+ endosomes mechanistically not fully resolved\", \"Whether endosomal signaling explains all KIR2DL4-dependent effects not tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identifying a LINE1 element upstream of HLA-G as a negative cis-regulatory silencer operating through DNA secondary structure provided a mechanism for restricting HLA-G expression to specific tissues.\",\n      \"evidence\": \"Human artificial chromosome system with single-copy genomic DNA manipulation and functional reporter assays\",\n      \"pmids\": [\"23002136\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How LINE1 silencing is overcome in trophoblasts not determined\", \"Trans-acting factors interacting with LINE1 secondary structure not identified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showing that KIR2DL4–HLA-G interaction induces NK senescence with a senescence-associated secretory phenotype that promotes vascular remodeling linked HLA-G to spiral artery remodeling during pregnancy.\",\n      \"evidence\": \"NK cell senescence assays, SASP characterization, KIR2DL4 signaling studies\",\n      \"pmids\": [\"24998350\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo validation in human pregnancy tissue lacking\", \"Relationship between NK senescence and the DNA-PKcs/Akt endosomal pathway not integrated\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrating that HLA-G+ extravillous trophoblasts directly induce FOXP3+ regulatory T cells from decidual CD4+ cells established a cellular mechanism for maternal immune tolerance at the implantation site.\",\n      \"evidence\": \"Cocultures of purified HLA-G+ EVT with matched decidual immune cell subsets, flow cytometry, microarray gene expression\",\n      \"pmids\": [\"26015573\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which HLA-G receptor on CD4+ T cells mediates Treg induction not identified\", \"Whether HLA-G-presented peptides influence Treg specificity unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identifying DNMT-1 as the methyltransferase responsible for HLA-G promoter hypermethylation-mediated silencing resolved a key epigenetic layer of HLA-G regulation.\",\n      \"evidence\": \"Bisulfite pyrosequencing, DNMT inhibitor treatment, DNMT-1 siRNA knockdown in trophoblast cell line\",\n      \"pmids\": [\"26116450\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How DNMT-1 is selectively recruited to HLA-G promoter not defined\", \"Interplay between DNMT-1 methylation and LINE1 silencer not examined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"CRISPR deletion of Enhancer L (12 kb upstream) abolished HLA-G expression, and chromatin conformation capture showed this enhancer physically loops to the promoter via CEBP/GATA factors, resolving how trophoblast-specific transcription is activated.\",\n      \"evidence\": \"MPRA, CRISPR/Cas9 deletion in JEG3 and primary trophoblasts, RNA-seq, DNase-seq, 3C, TF ChIP\",\n      \"pmids\": [\"27078102\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether additional enhancers contribute in primary trophoblasts not excluded\", \"How Enhancer L overcomes DNMT-1 and LINE1 repression not mechanistically linked\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis of HLA-G dimer engagement with each receptor, how Enhancer L activation overrides DNMT-1 methylation and LINE1 silencing during trophoblast differentiation, which receptor mediates HLA-G-driven Treg induction, and the relative in vivo contributions of shedding, exosomal release, and trogocytosis to systemic HLA-G-mediated tolerance.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No co-crystal structure of HLA-G dimer with ILT2, ILT4, or KIR2DL4\", \"Integration of epigenetic and enhancer-driven regulatory layers unresolved\", \"In vivo quantification of different soluble HLA-G generation mechanisms lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 4, 9, 11, 14, 17]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [3, 4, 9, 11, 14, 17, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 2, 7]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [5, 10]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 4, 9, 11, 16, 23]},\n      {\"term_id\": \"R-HSA-1474165\", \"supporting_discovery_ids\": [0, 21, 23, 24]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [17, 21]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [22, 24, 25]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ILT2\", \"ILT4\", \"KIR2DL4\", \"CD160\", \"HLA-E\", \"CD94\", \"B2M\"],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"HLA-G is a nonclassical MHC class I molecule with restricted expression on extravillous trophoblasts that functions as a master mediator of immune tolerance at the maternal–fetal interface and in other immunoprivileged contexts. Its truncated cytoplasmic tail impairs endocytosis, prolonging surface residence [PMID:9368631], and its primary transcript undergoes alternative splicing to produce at least four membrane-bound and three soluble isoforms, all capable of inhibiting NK- and CTL-mediated cytolysis [PMID:1570318, PMID:11290782]. HLA-G presents peptides via a defined XI/LPXXXXXL motif [PMID:8805247] and forms disulfide-linked dimers through Cys-42 [PMID:12454284]; it engages the inhibitory receptors ILT2 and ILT4 with 3–4-fold higher affinity than classical MHC-I to induce tolerogenic dendritic cells and regulatory T cells, KIR2DL4 from endosomes to elicit proangiogenic signaling, and CD8 on activated T cells to trigger Fas/FasL-mediated apoptosis [PMID:12853576, PMID:15770701, PMID:10190900, PMID:10843658]. Trophoblast-specific expression is governed by a distal enhancer (Enhancer L, ~12 kb upstream) occupied by CEBP/GATA factors and looping to the promoter, with additional regulation by IL-10-dependent transcription, DNMT-1-mediated promoter methylation, a LINE1-based silencing element, and a 3′ UTR 14-bp insertion polymorphism that modulates mRNA stability [PMID:27078102, PMID:10330285, PMID:26116450, PMID:23002136, PMID:14602228].\",\n  \"teleology\": [\n    {\n      \"year\": 1987,\n      \"claim\": \"Identification of HLA-G as a non-classical class I gene with a truncated cytoplasmic tail established it as structurally distinct from HLA-A/B/C and predicted unusual trafficking or signaling properties.\",\n      \"evidence\": \"Genomic cloning and sequencing revealing an in-frame stop codon shortening the cytoplasmic domain\",\n      \"pmids\": [\"3480534\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No protein expression data yet\", \"No functional consequence of tail truncation demonstrated\", \"Tissue distribution unknown\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Demonstrating that HLA-G protein is selectively expressed on first-trimester cytotrophoblasts but absent from lymphoid cells answered whether HLA-G had tissue-restricted expression and immediately implicated it in maternal–fetal immune regulation.\",\n      \"evidence\": \"2D gel electrophoresis and immunoprecipitation on trophoblast and lymphoid cells; independent cDNA cloning from extravillous trophoblast and BeWo choriocarcinoma\",\n      \"pmids\": [\"2326636\", \"2295808\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of tissue restriction unknown\", \"Functional role at the maternal–fetal interface not yet demonstrated\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Discovery of at least three alternatively spliced isoforms (including truncated forms lacking alpha2 or alpha2+alpha3 domains) expanded the functional repertoire of HLA-G beyond a single membrane-bound protein.\",\n      \"evidence\": \"RT-PCR with immunoprecipitation of [35S]-labeled proteins confirming three distinct protein products\",\n      \"pmids\": [\"1570318\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether truncated isoforms reach the cell surface and are functional was unresolved\", \"Soluble isoforms not yet characterized\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Defining the HLA-G peptide-binding motif (XI/LPXXXXXL) established that HLA-G presents peptides analogously to classical MHC-I, raising the question of whether its immunomodulatory function requires specific peptide loading.\",\n      \"evidence\": \"Peptide elution from HLA-G-expressing LCL721.221 transfectants, pool sequencing, and peptide-binding assays\",\n      \"pmids\": [\"8805247\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of physiologically presented peptides at the maternal–fetal interface unknown\", \"Whether peptide identity affects receptor engagement undetermined\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Functional evidence that HLA-G1 and HLA-G2 isoforms both inhibit NK cell lysis, combined with demonstration that the truncated cytoplasmic tail impairs endocytosis, established HLA-G as a stable surface-resident NK inhibitory ligand functioning through the alpha1 domain.\",\n      \"evidence\": \"NK cytolysis assays with HLA-G1/G2-transfected K562 cells across 20 donors; surface biotinylation and chimeric construct endocytosis assays\",\n      \"pmids\": [\"9144223\", \"9368631\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific inhibitory receptors mediating NK inhibition not yet identified\", \"Whether all truncated isoforms are functional was unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identification of ILT2, ILT4, and KIR2DL4 as three distinct HLA-G receptors, together with the indirect pathway via HLA-E/CD94-NKG2A, resolved how HLA-G inhibits diverse immune effector cell types through both direct and indirect recognition systems.\",\n      \"evidence\": \"ILT4 ITIM signaling assays; recombinant KIR2DL4 binding to HLA-G+ cells with functional transfer into NK-92; HLA-E leader-sequence mutagenesis combined with ILT2-Ig and CD94/NKG2A blocking\",\n      \"pmids\": [\"9531263\", \"10190900\", \"9933109\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative binding affinities for each receptor not yet measured\", \"Signaling pathways downstream of each receptor not characterized\", \"KIR2DL4 binding site on HLA-G unmapped\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Showing that soluble HLA-G1 induces apoptosis in activated CD8+ T cells via CD8-dependent upregulation of CD95L/Fas revealed a cytotoxic effector deletion mechanism distinct from receptor-mediated inhibition.\",\n      \"evidence\": \"Affinity-purified sHLA-G1 with CD95-Fc, ZB4, and CD8 mAb blocking experiments\",\n      \"pmids\": [\"10843658\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this pathway operates in vivo at the maternal–fetal interface not shown\", \"Threshold of sHLA-G1 concentration required for apoptosis undefined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of Cys-42 as the sole residue mediating HLA-G disulfide-linked dimerization defined a structural feature unique among MHC-I molecules that enhances receptor avidity.\",\n      \"evidence\": \"Site-directed mutagenesis (Cys42Ser) with surface biotinylation and DTT reduction\",\n      \"pmids\": [\"12454284\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether dimeric HLA-G has differential receptor-binding properties versus monomer not quantified\", \"Crystal structure of the dimer not yet available\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Quantitative SPR measurements showing 3–4-fold higher affinity of ILT2 and ILT4 for HLA-G versus classical MHC-I, combined with demonstration that ILT2/ILT4 compete with CD8, established the biophysical basis for preferential immune inhibition by HLA-G.\",\n      \"evidence\": \"Surface plasmon resonance with recombinant ILT2, ILT4, and multiple MHC-I; CD8 competition assay\",\n      \"pmids\": [\"12853576\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for enhanced affinity not elucidated\", \"Impact of dimerization on measured affinities not assessed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"The 14-bp insertion polymorphism in the HLA-G 3′ UTR was shown to generate a more stable spliced mRNA, providing a genetic mechanism for inter-individual variation in HLA-G expression levels.\",\n      \"evidence\": \"Actinomycin D mRNA stability assays in JEG-3 and transfected M8 melanoma cells\",\n      \"pmids\": [\"14602228\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether mRNA stability differences translate to proportional protein-level differences in vivo not demonstrated\", \"Trans-acting factors mediating differential stability not identified\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstration that HLA-G/ILT4 engagement arrests DC maturation, disrupts MHC-II presentation, and induces tolerogenic DCs that generate anergic T cells—prolonging allograft survival in ILT4-transgenic mice—linked HLA-G to adaptive immune tolerance induction beyond NK inhibition.\",\n      \"evidence\": \"Human monocyte-derived DC assays combined with ILT4-transgenic mouse allograft model\",\n      \"pmids\": [\"15770701\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular signaling cascade downstream of ILT4 in DCs incompletely defined\", \"Whether this pathway functions identically in human tissues in vivo not confirmed\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Soluble HLA-G5 secreted by MSCs in an IL-10-dependent manner was shown to suppress T-cell proliferation and expand FOXP3+ Tregs, extending HLA-G function beyond the trophoblast to MSC-mediated immunomodulation, while soluble HLA-G1 inhibited angiogenesis through CD160 in vitro and in vivo.\",\n      \"evidence\": \"Anti-HLA-G neutralizing antibody blocking in MSC–T cell cocultures; endothelial cell assays and rabbit corneal neoangiogenesis model with CD160 receptor binding\",\n      \"pmids\": [\"17932417\", \"17467060\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HLA-G5 is the principal effector of MSC immunosuppression or one of several redundant mechanisms unknown\", \"CD160 signaling pathway downstream of HLA-G binding not fully characterized\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"The finding that KIR2DL4 resides in endosomes and signals via DNA-PKcs/Akt after capturing soluble HLA-G revealed an unconventional endosomal immune signaling pathway, while LINE1-mediated chromatin silencing upstream of HLA-G added an epigenetic layer of expression control.\",\n      \"evidence\": \"Endosomal fractionation and kinase pathway analysis for KIR2DL4; human artificial chromosome system with single-copy LINE1 manipulation\",\n      \"pmids\": [\"22934097\", \"23002136\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"KIR2DL4 endosomal signaling characterized largely from one group; independent replication needed\", \"How LINE1 secondary structure recruits silencing factors not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Primary HLA-G+ extravillous trophoblasts were directly shown to expand resting FOXP3+ Tregs in decidual tissue, providing in situ evidence for HLA-G-driven tolerance at the maternal–fetal interface, while DNMT-1-mediated promoter methylation was identified as a mechanism that suppresses HLA-G in preeclampsia.\",\n      \"evidence\": \"FACS-purified primary EVT coculture with decidual immune cells and microarray profiling; bisulfite pyrosequencing with DNMT-1 siRNA/5-aza-CdR in trophoblast cells\",\n      \"pmids\": [\"26015573\", \"26116450\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether DNMT-1-mediated silencing is causally linked to preeclampsia pathogenesis or a secondary effect not established\", \"Relative contributions of individual immune cell types to Treg expansion not dissected\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"CRISPR/Cas9 deletion of Enhancer L (12 kb upstream) ablated HLA-G expression, and chromatin conformation capture showed Enhancer L loops to the promoter via CEBP/GATA factors, resolving the long-standing question of how trophoblast-specific transcription is achieved.\",\n      \"evidence\": \"MPRA, CRISPR/Cas9 deletion in JEG3 and primary trophoblasts, RNA-seq, DNase-seq, 3C, saturation mutagenesis\",\n      \"pmids\": [\"27078102\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Enhancer L operates in non-trophoblast contexts (e.g., tumors, MSCs) not tested\", \"Complete set of transcription factors required at Enhancer L not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include: (1) structural determination of how HLA-G dimers engage ILT2/ILT4 versus KIR2DL4; (2) the in vivo hierarchy among the multiple receptor pathways for maternal–fetal tolerance; (3) whether tumor exploitation of HLA-G recapitulates the same receptor/signaling axis as trophoblast-driven tolerance.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal structure of HLA-G dimer–receptor complex available\", \"In vivo redundancy among ILT2, ILT4, KIR2DL4, and HLA-E pathways not delineated\", \"Relative importance of membrane-bound versus soluble isoforms in tumor immune evasion not resolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [6, 8, 9, 10, 12, 15, 17]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [6, 9, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 4, 7, 13, 14]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [12, 18, 21, 30]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [23]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6, 8, 9, 10, 12, 15, 19, 21, 22, 25]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 19, 23]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"complexes\": [\n      \"MHC class I/beta2-microglobulin/peptide complex\",\n      \"HLA-G Cys42-linked homodimer\"\n    ],\n    \"partners\": [\n      \"ILT2\",\n      \"ILT4\",\n      \"KIR2DL4\",\n      \"B2M\",\n      \"CD8A\",\n      \"CD160\",\n      \"CD94\",\n      \"NKG2A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}